Mammalian cells for producing adeno-associated virus

Abstract

A mammalian cell comprising at least four distinct recombinant target sites (RTS), an adenovirus (Ad) gene comprising E1A, E1B or a combination thereof, and a promoter operably linked to the Ad gene, wherein the RTS, the Ad gene and the promoter are integrated into the chromosome; a method of using such a cell to generate a recombinant adeno-associated virus (rAAV) producer host cell; and a method of producing, packaging and purifying rAAV using the AAV producer host cell. [Selection Diagram] Figure 8

Description

[Technical field]

[0001]

[0001] This disclosure relates to a mammalian cell comprising at least four distinct recombination target sites (RTS), an adenovirus (Ad) gene comprising E1A, E1B or a combination thereof, and a promoter operably linked to the Ad genes, wherein the RTS, the Ad genes and the promoter are integrated into a chromosome. This disclosure also relates to methods of using the cells to generate recombinant adeno-associated virus (rAAV) producer cells, and methods of using the rAAV producer cells to produce, package and purify rAAV in the absence of live helper virus. [Background technology]

[0002]

[0002] The use of recombinant adeno-associated viruses (rAAVs) is being actively pursued in clinical development to enable long-lasting and efficient delivery of gene therapy products. Baculovirus-based platforms for rAAV production typically require variable and time-consuming raw materials. Triple transfection and transient expression in HEK293 are limited due to poor scalability. Existing scalable HeLa-based producer cell line processes require wild-type (wt) adenovirus 5 (Ad5) as a helper virus, but clearance of the helper virus from the final product is important from a safety perspective. When constructing cell lines producing rAAVs, the gene of interest and auxiliary helper genes may be transiently expressed or integrated into the host chromosome. Conventional DNA transduction pathways used to modify cell genomes are prone to unpredictable alterations and are not easily altered on demand for different viral serotypes.

[0003]

[0003] Therapeutic recombinant adeno-associated virus (AAV) constructs are replication defective and require co-infection with wild-type adenovirus (Ad) for replication and subsequent rounds of infection. The generation of therapeutic recombinant adeno-associated virus (rAAV) vectors generally requires the supply of three distinct components to the host: (i) the adeno-associated virus genes Rep / Cap, which provide replication and packaging elements, (ii) helper virus functions from the Ad genome for viral packaging, and (iii) a gene of interest (GOI) located between the 3' and 5' inverted terminal repeats (ITRs) of AAV. The Ad genes required for efficient gene expression, DNA replication and packaging are believed to include E1A, E1B, E2A, E4 and VA RNA. E1A is said to be the earliest gene product produced during Ad infection (Shenk, T. et al., Fields Virology, 3rd ed., 2211-2148(1996)). E1A is thought to function as a stepping stone to initiate viral replication by upregulating transcription from the AAV Rep gene promoters p5 and p19, and by activating the adenovirus early promoters for E1B, E2A, and E4. It is also thought that E1A is used to perform the function of transitioning host cells to the S phase of the cell cycle for viral DNA replication, since the proteins encoded by AAV (Rep and Cap) do not have this function. The deleterious effect of E1A is that it stabilizes p53, which further leads to apoptosis (Low et al., Genes & Dev. 7:535-545(1993)). Leak expression of E1A can also turn on Ad genes as well as AAV Rep genes. The latter has been reported to have cytostatic and cytotoxic properties, which makes it difficult to obtain stable cell lines from cells that constitutively express E1A. Control of E1A gene expression appears to be crucial for establishing helper virus-free AAV packaging cell lines.

[0004]

[0004] Various cell lines and approaches have been attempted to bring these elements together to produce rAAV. Among these various cell lines are the HEK293 and HeLa cell lines. Various approaches have also included the use of baculovirus systems. However, each cell line and approach has its own drawbacks, and none is an ideal platform for a robust, scalable rAAV production process.

[0005]

[0005] One rAAV production process uses HEK293 cells generated by transfection of primary embryonic kidney cells with physically sheared Ad5 DNA (Graham FL et al., J. Gen. Virol. 36:59-74(1977)). Genomic analysis has revealed that HEK293 cells carry an integrated fragment of the left end of the adenovirus genome (bases 1-4344) that contains the E1 region and additional flanking sequences (Louis N. et al., Virology 233:423-9(1997)). Several triple transfection processes have been used to transfect adherent HEK293 cells with plasmids containing the remaining essential elements. Although HEK293 can be used for rAAV production, adherent cell-based processes are difficult to scale up and cannot meet the growing need for vectors with multiple potencies, thus relying on transient transfection rather than stable producer cell lines.

[0006]

[0006] The second rAAV production process features the generation and selection of stably transfected HeLa cell clones that contain both AAV genes Rep / Cap and the GOI. These cell lines are then infected with wild-type Ad5 to allow packaging of rAAV particles. Although the method is scalable, the generation of these clones can be a lengthy, labor-intensive process, and removal of wild-type Ad5 virus from the final product of the process adds multiple steps to the process.

[0007]

[0007] A third rAAV production process relies on recombinant baculovirus for the introduction of AAV genes (Rep / Cap) and directly performs the helper virus functions required for rAAV production in SF9 insect cells. Although this method is scalable in suspension culture, it requires the generation of plaque-purified recombinant baculovirus constructs, thus lengthening the time for product development.

[0008]

[0008] A novel and efficient platform for rAAV production that addresses these shortcomings, provides a rapid process for generating stable producer cell lines in the desired AAV serotype, and further provides high-yield, scale-up production without the addition of live helper virus is needed to provide high-quality vectors for use in both preclinical and clinical trials.

[0009]

[0009] Type I interferons (IFNs) were the first cytokines to be discovered and named for their potent ability to "block" viral replication. Many viral products can block IFN-associated signals, such as the influenza NS1 protein and vaccinia virus E3L protein, which inhibit protein kinase R (PKR), and the soluble IFN-α / β receptor decoys encoded by vaccinia virus.

[0010]

[0010] Chinese hamster ovary (CHO) cells (Puck, J. Exp. Med., 108:259-268(1958)) are a well-characterized cell line that is often used for industrial production of recombinant proteins from mammalian cells due to their high productivity, robust nature, and ease of handling in industrial safety and usage records (Birch and Racher, Adv. Drug Delivery Rev., 58:671-685(2006)). However, CHO cells have not previously been used in the production of rAAV.

[0011]

[0011] Various publications are cited herein, the disclosures of which are incorporated herein by reference in their entireties. Summary of the Invention

[0012] [Brief Description of the Invention]

[0012] In some embodiments, the disclosure provides a mammalian cell comprising (i) at least four distinct recombination target sites (RTS), (ii) adenovirus (Ad) genes including E1A, E1B or a combination thereof, and (iii) a promoter operably linked to the Ad genes, wherein the RTS, Ad genes and promoter are integrated into a chromosome. In some embodiments, the cell is a mouse cell, a human cell, a Chinese Hamster Ovary (CHO) cell, a CHO-K1 cell, a CHO-DXB11 cell, a CHO-DG44 cell, a CHOK1SV™ cell including all variants (Lonza, Slough, UK), a CHOK1SV GS-KO™ (glutamine synthetase knockout) cell including all variants (Lonza, Slough, UK), a HEK293 cell including adherent and suspension adapted variants, a HeLa cell or a HT1080 cell. In some embodiments, the cell comprises four RTSs. In some embodiments, the cell comprises six RTSs. In some embodiments, the at least one RTS is selected from the group consisting of SEQ ID NOs: 1-30. In some embodiments, the at least one RTS, Ad gene and promoter are integrated into a single chromosomal locus. In some embodiments, the chromosomal locus is Fer1L4, ROSA26, HGPRT, DHFR, COSMC, LDHa, MGAT1, GRIK1, NL1, NL2, the first intron of MID1 on the X chromosome, or Enhanced Expression and stability regions (EESYR, see e.g., U.S. Pat. No. 7,771,997). In some embodiments, the cell comprises a site-specific recombinase gene. In some embodiments, the site-specific recombinase gene is integrated into the chromosome. In some embodiments, the cell comprises a second Ad gene, and the second Ad gene is integrated into the chromosome. In some embodiments, the second Ad gene comprises E1A, E1B, E2A, E4, VA, MIR342, or a combination thereof. In some embodiments, the second Ad gene is from Ad5. In some embodiments, the second Ad gene is located between the two RTSs.In some embodiments, the cell further comprises an adeno-associated virus (AAV) gene, and the AAV gene is integrated into the chromosome. In some embodiments, the AAV gene comprises Rep, Cap, or a combination thereof. In some embodiments, the AAV gene is from adeno-associated virus type 2. In some embodiments, the AAV gene is located between two RTSs. In some embodiments, the cell further comprises an AAV vector cassette, and the AAV vector cassette is integrated into the chromosome. In some embodiments, the AAV vector cassette comprises a reporter gene, a selection gene, a gene of therapeutic interest, or a combination thereof. In some embodiments, the AAV vector cassette is located between two RTSs. In some embodiments, the cell is substantially free of helper virus.

[0013]

[0013] In some embodiments, the disclosure provides a mammalian cell comprising (i) at least four distinct recombination target sites (RTSs); (ii) Ad genes E2A, E4, VA, MIR342 or a combination thereof; and (iii) a promoter operably linked to the Ad gene, wherein the RTSs, Ad genes and promoters are integrated into a chromosome. In some embodiments, the cell is a mouse cell, a human cell, a Chinese Hamster Ovary (CHO) cell, a CHO-K1 cell, a CHO-DXB11 cell, a CHO-DG44 cell, a CHOK1SV™ cell including all variants, a CHOK1SV GS-KO™ (glutamine synthetase knockout) cell including all variants, a HEK293 cell including adherent and suspension adapted variants, a HeLa cell or a HT1080 cell. In some embodiments, the cell comprises four RTSs. In some embodiments, the cell comprises six RTSs. In some embodiments, at least one RTS is selected from the group consisting of SEQ ID NOs: 1-30. In some embodiments, the RTS, Ad gene and promoter are integrated into a single chromosomal locus. In some embodiments, the chromosomal locus is Fer1L4, ROSA26, HGPRT, DHFR, COSMC, LDHa, MGAT1, GRIK1, NL1, NL2, the first intron of MID1 on the X chromosome, or the expression enhancing and stability region (EESYR). In some embodiments, the cell comprises a site-specific recombinase gene. In some embodiments, the site-specific recombinase gene is integrated into the chromosome. In some embodiments, the cell further comprises a second Ad gene, the second Ad gene is integrated into the chromosome. In some embodiments, the second Ad gene comprises E1A, E1B, E2A, E4, VA, MIR342, or a combination thereof. In some embodiments, the second Ad gene is from Ad5. In some embodiments, the second Ad gene is located between two RTSs. In some embodiments, the cells further comprise adeno-associated virus (AAV) genes, wherein the AAV genes are integrated into the chromosome, hi some embodiments, the AAV genes comprise Rep, Cap, or a combination thereof.In some embodiments, the AAV gene is from adeno-associated virus type 2. In some embodiments, the AAV gene is located between two RTSs. In some embodiments, the cell further comprises an AAV vector cassette, and the AAV vector cassette is integrated into a chromosome. In some embodiments, the AAV vector cassette comprises a reporter gene, a selection gene, a gene of therapeutic interest, or a combination thereof. In some embodiments, the AAV vector cassette is located between two RTSs. In some embodiments, the cell is substantially free of helper virus.

[0014] In some embodiments, the disclosure provides a mammalian cell comprising (i) at least four distinct recombination target sites (RTS) and (ii) adeno-associated virus (AAV) genes comprising Rep, Cap or a combination thereof, wherein the RTS and AAV genes are integrated into a chromosome. In some embodiments, the AAV genes are from adeno-associated virus type 2. In some embodiments, the cell is a mouse cell, a human cell, a Chinese Hamster Ovary (CHO) cell, a CHO-K1 cell, a CHO-DXB11 cell, a CHO-DG44 cell, a CHOK1SV™ cell including all variants, a CHOK1SV GS-KO™ cell including all variants, a HEK293 cell including adherent and suspension adapted variants, a HeLa cell or a HT1080 cell. In some embodiments, the cell comprises four RTSs. In some embodiments, the cell comprises six RTSs. In some embodiments, at least one RTS is selected from the group consisting of SEQ ID NOs: 1-30. In some embodiments, the RTS and AAV are integrated into a single chromosomal locus. In some embodiments, the chromosomal locus is Fer1L4, ROSA26, HGPRT, DHFR, COSMC, LDHa, MGAT1, GRIK1, NL1, NL2, the first intron of MID1 on the X chromosome, or the expression enhancing and stability region (EESYR). In some embodiments, the cell comprises a site-specific recombinase gene. In some embodiments, the site-specific recombinase gene is integrated into the chromosome. In some embodiments, the cell further comprises an Ad gene and a promoter operably linked to the Ad gene, whereby the Ad gene and the promoter are integrated into the chromosome. In some embodiments, the Ad gene comprises E1A, E1B, E2A, E4, VA, MIR342, or a combination thereof. In some embodiments, the Ad gene is from Ad5. In some embodiments, the AAV gene is located between the two RTSs. In some embodiments, the cell further comprises an AAV vector cassette, where the AAV vector cassette is integrated into the chromosome.In some embodiments, the AAV vector cassette comprises a reporter gene, a selection gene, a therapeutic gene, or a combination thereof. In some embodiments, the AAV vector cassette is located between two RTSs. In some embodiments, the cell is substantially free of helper virus.

[0015]

[0015] In some embodiments, the disclosure provides a Chinese hamster ovary (CHO) cell comprising six distinct recombination target sites (RTS), at least one RTS selected from the group consisting of SEQ ID NOs: 1-30; an adenovirus (Ad) gene comprising E1A and E1B; and a promoter operably linked to the Ad gene, wherein the RTS, Ad gene, and promoter are integrated into a chromosome; a second Ad gene comprising E2A, E4, VA, and MIR342, the second Ad gene being integrated into the chromosome and located between the two RTSs; an adeno-associated virus (AAV) gene comprising Rep and Cap, the AAV gene being integrated into the chromosome and located between the two RTSs; and an AAV vector cassette comprising a reporter gene, a selection gene, or a gene of therapeutic interest, the AAV vector cassette being integrated into the chromosome and located between the two RTSs.

[0016]

[0016] In some embodiments, the present disclosure provides a Chinese hamster ovary (CHO) cell comprising adenovirus (Ad) genes including E1A and E1B and a promoter operably linked to the Ad genes, a second Ad gene including E2A, E4, VA and MIR342, adeno-associated virus (AAV) genes including Rep and Cap, and an AAV vector cassette comprising a reporter gene, a selection gene, a therapeutic gene or a combination thereof.

[0017]

[0017] In some embodiments, the disclosure provides a method for producing a recombinant adeno-associated virus (rAAV) producer cell comprising the steps of: providing a cell comprising at least four distinct recombination target sites (RTS), an adenovirus (Ad) gene comprising E1A, E1B or a combination thereof, and a promoter operably linked to the Ad gene, wherein the RTS, the Ad gene and the promoter are integrated into a chromosome; transfecting the provided cell with a vector comprising a replaceable cassette encoding an adeno-associated virus (AAV) gene, a second Ad gene, an AAV vector cassette or a combination thereof; integrating the replaceable cassette into the chromosome; and selecting rAAV producer cells having the replaceable cassette integrated into the chromosome. In some embodiments, the transfection is with two vectors, a first vector comprising a replaceable cassette comprising the second Ad gene and the AAV gene, and a second vector comprising a replaceable cassette comprising the AAV vector cassette. In some embodiments, the transfection is performed with two vectors, a first vector comprising a replaceable cassette comprising a second Ad gene and a second vector comprising a replaceable cassette comprising an AAV gene. In some embodiments, the transfection is performed with three vectors, a first vector comprising a replaceable cassette comprising a second Ad gene, a second vector comprising a replaceable cassette comprising an AAV gene, and a third vector comprising a replaceable cassette comprising an AAV vector cassette. In some embodiments, each replaceable cassette further comprises two RTSs that match the two RTSs of the cell. In some embodiments, the second Ad gene comprises E1A, E1B, E2A, E4, VA, MIR342, or a combination thereof. In some embodiments, the AAV gene comprises Rep, Cap, or a combination thereof. In some embodiments, the AAV vector cassette comprises a reporter gene, a selection gene, a gene of therapeutic interest, or a combination thereof.

[0018]

[0018] In some embodiments, the disclosure provides a method for producing a recombinant adeno-associated virus (rAAV), comprising (i) infecting a host cell with rAAV, (ii) producing rAAV packaged with an AAV vector cassette, and (iii) purifying the packaged rAAV, wherein the host cell comprises at least four distinct recombination target sites (RTS), an adenovirus (Ad) gene comprising E1A, E1B, or a combination thereof, a promoter operably linked to the Ad gene, wherein the RTS, the Ad gene, and the promoter are integrated into a chromosome, a second Ad gene comprising E1A, E1B, E2A, E4, VA, MIR342, or a combination thereof, an adeno-associated virus (AAV) gene comprising Rep, Cap, or a combination thereof, and an AAV vector cassette comprising a reporter gene, a selection gene, a therapeutic gene, or a combination thereof. In some embodiments, a live wild-type helper virus is not required for the production and packaging of rAAV. In some embodiments, expression of E1A is not required for rAAV production. 9 vg / mL of active AAV is obtained after purification. [Brief description of the drawings]

[0019] [Figure 1A] Figure 1 shows the production of recombinant adeno-associated virus (rAAV) in HEK293 and CHOK1SV GS-KO™ cells. Triple transfection with plasmids pAAV-GFP (AAV-400, Cell Biolabs), pRC2-mi342 (6234, Clontech) and pHelper (6234, Clontech) was accomplished in HEK293 cells. Double transfection with helper virus co-infection (wt Ad5) pAAV-GFP (AAV-400, Cell Biolabs) and pRC2-mi342 (6234, Clontech) was accomplished in CHOK1SV GS-KO™. Figure 1A shows a schematic diagram of the experimental design. [Figure 1B] Figure 1 shows the production of recombinant adeno-associated virus (rAAV) in HEK293 and CHOK1SV GS-KO™ cells. Triple transfection with plasmids pAAV-GFP (AAV-400, Cell Biolabs), pRC2-mi342 (6234, Clontech) and pHelper (6234, Clontech) was completed in HEK293 cells. Double transfection with helper virus (wt Ad5) pAAV-GFP (AAV-400, Cell Biolabs) and pRC2-mi342 (6234, Clontech) was completed in CHOK1SV GS-KO™. FIG. 1B shows detection of green fluorescent protein (GFP) signal in transfected CHOK1SV GS-KO™ cells (left) and HEK293 cells infected with lysates from transfected CHOK1SV GS-KO™ cells (right). [Figure 1C] Figure 1 shows the production of recombinant adeno-associated virus (rAAV) in HEK293 and CHOK1SV GS-KO™ cells. Triple transfection with plasmids pAAV-GFP (AAV-400, Cell Biolabs), pRC2-mi342 (6234, Clontech) and pHelper (6234, Clontech) was completed in HEK293 cells. Double transfection with helper virus co-infection (wt Ad5) pAAV-GFP (AAV-400, Cell Biolabs) and pRC2-mi342 (6234, Clontech) was completed in CHOK1SV GS-KO™. Figure 1C shows the quantification of rAAV titers in CHOK1SV GS-KO™ and HEK293 (control) cells by qPCR analysis of viral genomic DNA. [Diagram 2] Figure 2 shows a diagram of the pMF30 vector. E1A is present in the TET inducible vector carrying the GS selection marker. [Diagram 3]Figure 3 shows a diagram of the pMF23 vector. E1B is present in the constitutive vector carrying the PAC selection marker. [Figure 4] Figure 4 shows a diagram of the pXC17.4_17Ad5PerProKZ vector. E1A and E1B were expressed from a single promoter as described in Qiao et al., J. Virol. 76:1904-13(2002) (the viral control region between the two genes and the viral promoter region (nucleotides 498-3635) located between the E1A and E1B coding sequences have been retained). Annotations correspond to the coordinates described in Qiao et al., J. Virol.76:1904-13(2002). [Figure 5A] Figure 5 shows the construction of CHOK1SV GS-KO™ pools that express wild-type Ad5 E1A and E1B to enable rAAV production in these cells without helper virus. Figure 5A is a schematic of the experimental design. [Figure 5B] Figure 5 shows the construction of CHOK1SV GS-KO™ pools that express wild-type Ad5 E1A and E1B to enable rAAV production in these cells without helper virus. Figure 5B shows agarose gel analysis of genomic PCR products for E1A in HEK293F, HEK293L, CHOK1SV GS-KO™, and CHOK1SV GS-KO™ MOCK and CHOK1SV GS-KO™ (E1A_E1B) pools. [Figure 5C] Figure 5 shows the construction of CHOK1SV GS-KO™ pools that express wild-type Ad5 E1A and E1B to enable rAAV production in these cells without helper virus. Figure 5C shows agarose gel analysis of genomic PCR products for E1B in HEK293F, HEK293L, CHOK1SV GS-KO™ hosts and CHOK1SV GS-KO™ MOCK and CHOK1SV GS-KO™ E1A_E1B pools. [Figure 5D]Figure 5 shows the construction of CHOK1SV GS-KO™ pools that express wild-type Ad5 E1A and E1B to enable rAAV production in these cells without helper virus. Figure 5D shows agarose gel analysis of RT-PCR products for E1A in doxycycline-treated HEK293F, HEK293L, CHOK1SV GS-KO™ hosts, and CHOK1SV GS-KO™ MOCK and CHOK1SV GS-KO™ E1A_E1B pools. [Figure 5E] Figure 5 shows the construction of CHOK1SV GS-KO™ pools that express wild-type Ad5 E1A and E1B to enable rAAV production in these cells without helper virus. Figure 5E shows agarose gel analysis of RT-PCR products for E1B in doxycycline-treated HEK293F, HEK293L, CHOK1SV GS-KO™, and CHOK1SV GS-KO™ MOCK and CHOK1SV GS-KO™ E1A_E1B pools. [Figure 5F] Figure 5 shows the construction of CHOK1SV GS-KO™ pools that express wild-type Ad5 E1A and E1B to enable rAAV production in these cells without helper virus. Panel F shows Western blot analysis of protein lysates for E1A and β-actin in CHOK1SV GS-KO™ MOCK and CHOK1SV GS-KO™ E1A_E1B pools. [Figure 6] FIG. 6 shows vector diagrams for pRC2-miRNA342 (6234, Clontech) (FIG. 6A), pHelper (6234, Clontech) (FIG. 6B), and pAAV-GFP (AAV-400, Cell Biolabs) (FIG. 6C). [Figure 7]FIG. 7 shows a schematic diagram of three independently addressable site-specific integration sites (SSIS) in the site-specific integration cell lines CHOK1SV GS-KO™ and HEK293. FIG. 7A shows the layout of landing pad 1 containing single or dual function report / marker genes. The reporter gene is under the control of the SV40E promoter and has the SV40 polyA sequence. For recombinase-mediated cassette exchange (RMCE), incompatible Frt sites are located between the SV40 promoter and the hpt-eGFP gene (Frt-A) and 5′ to the SV40 polyA sequence (Frt-B). FIG. 7B and FIG. 7C show the layout of the incompatible Frt sites (C, D, E, and F) and subsequent landing pads containing different reporters that allow independent targeting of payload sequences. In this case, Frt sites A to F can be any of those listed in Table 2. [Figure 8] FIG. 8 shows a systematic outline of the method for preparing CHOK1SV GS-KO™-AAV producer cells. Adenovirus (Ad) genes (helper genes), AAV genes (Rep / Cap) and AAV vector cassettes (e.g., ITR-GOI-ITR) are introduced using SSIS, and Ad genes (E1A / E1B) are further introduced into CHOK1SV GS-KO™ at another site together with an inducible promoter. In this case, Frt sites A-F can be any of those listed in Table 2. FIG. 8A shows the single site arrangement of CHOK1SV GS-KO™ and HEK293 host. Ad helper genes are integrated by SSIS, and GOI / Rep / Cap genes are transiently expressed from a plasmid. FIG. 8B shows the double site arrangement of CHOK1SV GS-KO™ and HEK293 host. The Ad helper and Rep / Cap genes are integrated in two separate SSISs and the GOI is transiently expressed from a plasmid. Figure 8C shows the triple site configuration of CHOK1SV GS-KO™ and the HEK293 host. The helper, Rep / Cap and GOI genes are integrated in three separate SSISs. In some cases, E1A and E1B genes are integrated in the SSISs to enhance expression. [Figure 9]9 shows a schematic of rAAV production in CHOK1SV GS-KO™ site-specific integration (SSI) hosts using site-specific integration of the GOI and Rep / Cap genes at different sites. To produce rAAV, CHOK1SV GS-KO™ SSI hosts were infected with wild-type Ad5 to provide helper gene functions required for rAAV replication. [Figure 10]FIG. 10 shows a schematic of the GOI vector and four designs of Rep / Cap genes for site-specific integration in CHOK1SV GS-KO™ host. All vectors are flanked by two Frt sites, allowing for the introduction of SSI into CHOK1SV GS-KO™ SSI host cells. FIG. 10A shows diagrammatically the construction of vector pLMC31 (encoding a rAAV vector with an eGFP reporter gene flanked by ITRs at both ends of the AAV cassette). The selection marker for this vector is the neomycin phosphotransferase I gene, and Frt sites are positioned for NL1 targeting. FIG. 10B shows diagrammatically the construction of vector pLMC32 (encoding the AAV2 Rep / Cap genes). This vector contains a minimal p5 promoter (open square) 5′ to Rep, including two enhancer elements, to reduce Rep expression and suppress rAAV production, and a complete p5 promoter (closed and open square) 3′ to Cap, to enhance Cap expression. FIG. 10C shows diagrammatically the construction of vector pLMC33 (encoding the AAV2 Rep / Cap genes). This vector contains a minimal p5 promoter (white squares) 5′ to Rep and a p5mut promoter (black and grey squares) 3′ to Cap, in which the TATA box has been mutated to GGGGGGG to reduce promoter activity. FIG. 10D shows diagrammatically the construction of vector pLMC34, again encoding the AAV2 Rep / Cap genes. The vector contains a wild-type p5 promoter (white and black squares) 5′ to Rep and a mutated p5 promoter (black and grey squares) 3′ to Cap. FIG. 10E shows diagrammatically the construction of vector pLMC35, again encoding the AAV2 Rep / Cap genes. This vector contains a mutated p5 promoter (black and grey squares) 5′ to Rep and 3′ to Cap. The selectable marker in pLMC32 to pLMC35 is the GS cDNA, with an Frt site positioned for targeting to Fer1L4. [Figure 11]Figure 11 shows protein expression of E1A, Rep and Cap in HEK293 and CHOK1SV GS-KO™ cells by Western blot analysis. HEK293 cells were transfected with pHelper (6234, Clontech), GOI (pLMC31) and one Rep-Cap vector (pLMC32-35) or triple transfected with pHelper (6234, Clontech), pRC2-mi342 (6234, Clontech) and pAAV-GFP (AAV-400, Cell Biolabs). CHOK1SV GS-KO™ cells were infected with wild-type Ad5 and transfected with the GOI (pLMC31) and one Rep-Cap vector (pLMC32-35), or infected with wild-type Ad5 and transfected with pRC2-mi342 (6234, Clontech) and pAAV-GFP (AAV-400, Cell Biolabs). Three days after transfection, protein lysates were analyzed by Western blotting. Figure 11A shows the levels of three E1A isoforms: E1A 289R, E1A 243R, and E1A 171R (Radko et al. (2015) PLoS One. 10:e0140124). E1A protein levels were detected using a mouse anti-E1A antibody (Abcam, ab33183) diluted 1:1000. The molecular weights of E1A, Rep and Cap protein isoforms are shown in brackets. There was no change in E1A protein levels in HEK293 or CHOK1SV GS-KO™ cells transfected with the different vectors, but the protein levels of each E1A isoform differed between HEK293 and CHOK1SV GS-KO™ cells. Figure 11B shows the levels of Rep78 and Rep52 proteins. Rep protein levels were detected using a mouse anti-Rep antibody (ARP, 03-61069) diluted 1:1000. The molecular weights are shown in brackets.Rep52 protein levels were unchanged in HEK293 or CHOK1SV GS-KO™ cells transfected with the different vectors, whereas Rep78 protein levels were higher in cells transfected with pLMC34 and pLMC35. Figure 11C shows the levels of the three Cap isoforms, VP1, VP2 and VP3, using mouse anti-Cap antibody (ARP, 03-61058) diluted at 1:1000. Molecular weights are shown in brackets. VP3 protein levels were unchanged in HEK293 cells transfected with the different vectors, and VP1 and VP2 were undetectable in HEK293 cells. VP1, VP2 and VP3 were undetectable in CHOK1SV GS-KO™ cells. Figure 11D shows the β-actin loading control, using mouse anti-β-actin antibody (TFS, MA5-1573) diluted at 1:1000. [Figure 12]Figure 12 shows the infectivity of rAAV produced by HEK293 and CHOK1SV GS-KO™ cells. HEK293 cells were triple transfected with Rep / Cap, GOI, and pHelper (6234, Clontech). CHOK1SV GS-KO™ cells were transfected with Rep / Cap and GOI and infected with wild-type Ad5. Three days after transfection, an equal amount of the collected crude rAAV was used to infect HEK293 cells. Two days after transduction, green fluorescence and bright field images were obtained. The green fluorescence is emitted by GOI-packaged rAAV. The scale bar in the figure represents 50 μm. The infectivity of rAAV produced by triple-transfected HEK293 cells (pHelper (6234, Clontech), pRC2-mi342 (6234, Clontech), and pAAV-GFP (AAV-400, Cell Biolabs)) (top panel) was higher than that produced by transfected CHOK1SV GS-KO™ cells (third panel). Notably, the infectivity of rAAV produced by HEK293 cells transfected with pLMC32-35 was higher than that produced by HEK293 cells transfected with pRC2-mi342 (6234, Clontech) (top panel). [Figure 13]Figure 13 shows the construction of pools from CHOK1SV GS-KO™ SSI hosts with GOI SSI and one of four Rep-Cap configurations. Pools were generated in two stages. In stage 1, part 1, CHOK1SV GS-KO™ SSI hosts were transfected with FLP recombinase vector (pMF4) and one Rep-Cap vector (pLMC32-35) and then selected in glutamine-free medium. In stage 1, part 2, CHOK1SV GS-KO™ SSI hosts were transfected with FLP recombinase vector (pMF4), one Rep-Cap vector (pLMC32-35) and GOI vector (pLMC31) and then selected in glutamine-free medium containing geneticin (500 μg / mL or 750 μg / mL). These were designated the "A" pools. In step 2, 4 to 7 of the "A" pool were transfected with FLP recombinase (pMF4) and the GOI vector (pLMC31) and then selected in medium containing geneticin (400 μg / mL). These were designated the "B" pool. [Figure 14] Figure 14 shows a schematic of primer sites for detection of targeted SSI and remaining (non-exchanged) landing pads. Primer set P5 was designed to detect specific Rep / Cap integration into the landing pad located in the Fer1L4 gene. The expected product size is 1524 bp. Primer set P6 was designed to detect the remaining landing pad. The expected product size is 487 bp. Primer set P7 was designed to detect specific GOI integration into the landing pad located in the NL1 locus. The expected product size is 1446 bp. Primer set P8 was designed to detect the remaining NL1 landing pad. The expected product size is 809 bp. [Figure 15]Figure 15 shows agarose gel analysis of genomic DNA PCR products for Rep / Cap integration into the Fer1L4 landing pad. Genomic DNA was recovered from "A" pool, "B" pool, CHOK1SV GS-KO™ and CHOK1SV GS-KO™ SSI hosts and then amplified by PCR using primer set 5 or 6. PCR products were separated by agarose gel electrophoresis. Figure 15A shows agarose gel analysis of genomic DNA PCR products for specific Rep / Cap integration into the landing pad located in the Fer1L4 gene using primer set P5. The expected product size is 1524bp. The results show specific Rep / Cap integration into the landing pad located in the Fer1L4 gene in pools 4, 5, 6, 7, 9, 11, 17, 18, 19, 21 of "A" pool and all of the "B" pools analyzed. As expected, specific Rep / Cap integration was not detected in CHOK1SV GS-KO™ and CHOK1SV GS-KO™ SSI hosts. Figure 15B shows agarose gel analysis of genomic DNA PCR products using primer set P6 for the remaining landing pad of the Fer1L4 gene. The expected product size is 487 bp. The results show incomplete Rep / Cap integration into some remaining landing pads and landing pads located in the Fer1L4 gene in all of the "A" pools except 18 and all of the "B" pools. A smaller PCR product was present in 19 of the "A" pools, indicating loss of some of the sequence. As expected, the landing pad of Fer1L4 was amplified in CHOK1SV GS-KO™ cells but not detected in the CHOK1SV GS-KO™ SSI host. [Figure 16]Figure 16 shows agarose gel analysis of genomic DNA PCR products for GOI integration into the NL1 landing pad. Genomic DNA was recovered from the "A" pool, the "B" pool, CHOK1SV GS-KO™ and CHOK1SV GS-KO™ SSI hosts and then amplified by PCR using primer set 7 or 8. PCR products were separated by agarose gel electrophoresis. Figure 16A shows agarose gel analysis of genomic DNA PCR products for GOI integration into the NL1 landing pad using primer set P7. The expected product size is 1446 bp. The results show specific GOI integration into the landing pads located at all NL1 loci in the "B" pool but not in the "A" pool. As expected, specific GOI integration was not detected in the CHOK1SV GS-KO™ and CHOK1SV GS-KO™ SSI hosts. FIG. 16B shows agarose gel analysis of genomic DNA products using the P8 primer set for the remaining NL1 landing pad. The expected product size is 809 bp. The results show incomplete GOI integration into some of the remaining landing pads and landing pads located in the NL1 gene in all of the "A" pools except 11 and all of the "B" pools. The results show that the NL1 landing pad was incomplete in "A" pool 11 and the GOI was not integrated into the landing pad. As expected, the NL1 landing pad was amplified in CHOK1SV GS-KO™ cells but was not detected in the CHOK1SV GS-KO™ SSI host. [Figure 17]Figure 17 shows protein expression of E1A, Rep and Cap in CHOK1SV GS-KO™ cells infected with wild-type Ad5 by Western blot analysis. Pools "A" and "B" were infected with wild-type Ad5 for 3 days and then harvested for E1A, Rep, Cap and β-actin protein expression analysis. Figure 17A shows the levels of three isoforms, E1A 289R, E1A 243R and E1A 171R. E1A protein levels were detected using a mouse anti-E1A antibody (Abcam, ab33183) diluted 1:1000. The molecular weights of E1A, Rep and Cap protein isoforms are shown in brackets. The levels of all three E1A isoforms were comparable in all pools and slightly higher in CHOK1SV GS-KO™ cells. Figure 17B shows the levels of Rep78 and Rep52 proteins. Rep protein levels were detected using mouse anti-Rep antibody (ARP, 03-61069) diluted 1:1000. Molecular weights are shown in brackets. Rep78 was not detectable. Rep52 was detected (indicated with *) in "A" pool 13 and "B" pools 6, 7, 8 and 10. Figure 11C shows the levels of the three Cap isoforms, VP1, VP2 and VP3, using mouse anti-Cap antibody (ARP, 03-61058) diluted 1:1000. Molecular weights are shown in brackets. VP1, Vp2 and VP3 were not detected. Figure 17D shows the β-actin loading control using mouse anti-β-actin antibody (TFS, MA5-1573) diluted 1:1000. [Figure 18]Figure 18 shows a schematic diagram of primer sites for detection of AAV2 Rep and Cap mRNA. Primer set P1 is for Rep78 and Rep68. Primer set P2 is for Rep78, Rep68, Rep52 and Rep40. Primer set P3 is for Rep78 and Rep52. Primer set P4 is for total Rep and Cap. * indicates alternative ACG codons used to produce VP3. The AAV2 genome structure was adjusted with reference to Samulski and Muzyczka., Annu. Rev. Virol. 1:427-451(2014). [Figure 19]Figure 19 shows mRNA expression analysis for Rep-Cap and Ad5 helper genes from transfected HEK293 and CHOK1SV GS-KO™ cells. HEK293 cells were triple transfected with pRC2-mi342 (6234, Clontech), pAAV-GFP (AAV-400, Cell Biolabs) vectors (black bars). CHOK1SV GS-KO™ cells were transfected with pRC2-mi342 and pAAV-GFP and infected with wild-type Ad5 (white bars). Controls included HEK293 or CHOK1SV GS-KO™ cells transfected with pRC2-mi342 (top left bar). cDNA was prepared and subjected to RT-qPCR analysis for Rep / Cap and Ad helper genes. Expression data were internally normalized by β-actin and then compared to HEK293 control samples. Primer sequences are shown in Figure 21. Figure 19A shows mRNA levels of Rep78 and Rep68. After triple transfection, ~6-fold and ~5-fold induction (respectively) was observed in HEK293 and CHOK1SV GS-KO™ cells. Figure 19B shows mRNA levels of Rep78, Rep68, Rep52 and Rep40. After triple transfection, ~11-fold and ~5-fold induction (respectively) was observed in HEK293 and CHOK1SV GS-KO™ cells. Figure 19C shows mRNA levels of Rep78 and Rep52. After triple transfection, ~17-fold and ~4-fold induction (respectively) was observed in HEK293 and CHOK1SV GS-KO™ cells. Figure 19D shows mRNA levels of total Rep and Cap. After triple transfection, ~20-fold and ~7-fold induction was observed in HEK293 and CHOK1SV GS-KO™ cells (respectively). Figure 19E shows E1A mRNA levels. After triple transfection, ~1-fold induction was observed in HEK293. E1A mRNA was not detected in control CHOK1SV GS-KO™ cells and was detected after transfection and infection with wild-type Ad5.FIG. 19F shows E1B-19K mRNA levels. After triple transfection, ~1-fold induction was observed in HEK293. E1B-19K mRNA was not detected in control CHOK1SV GS-KO™ cells and was detected after transfection and infection with wild-type Ad5. FIG. 19G shows E1B-55K mRNA levels. After triple transfection, ~1-fold induction was observed in HEK293. E1B-55K mRNA was not detected in control CHOK1SV GS-KO™ cells and was detected after transfection and infection with wild-type Ad5. FIG. 19H shows E2A mRNA levels. E2A mRNA was not detectable in control samples and was present after triple transfection. FIG. 19I shows E4 mRNA levels. E4 mRNA was not detectable in control samples and was present after triple transfection. FIG. 19J shows VAI mRNA levels. VAI mRNA was undetectable in control samples and was present after triple transfection. FIG. 19K shows VAII mRNA levels. VAII mRNA was undetectable in control samples and was present after triple transfection. All observed mRNA levels were lower in CHOK1SV GS-KO™ compared to HEK293 cells, except for E4 (FIGS. 19A-K). These data indicate that Rep-Cap mRNA induction and expression was lower in CHOK1SV GS-KO™ cells compared to HEK293 cells. [Figure 20]Figure 20 shows the titers of rAAV from triple transfected HEK293 and CHOK1SV GS-KO™ cells. HEK293 cells were transfected with pHelper (6234, Clontech), and one of pLMC32-35 or pRC-mi342 (6234, Clontech), and pLMC31 or pAAV-GFP (AAV-400, Cell Biolabs) vectors. CHOK1SV GS-KO™ cells were infected with wild-type Ad5, one of pLMC32-35 or pRC-mi342 (6234, Clontech), and pLMC31 or pAAV-GFP (AAV-400, Cell Biolabs) vectors. DNA was extracted 3 days after transfection and subjected to TaqMan-qPCR analysis for AAV expression. The titers of AAV produced by CHOK1SV GS-KO™ cells were lower than those produced by HEK293 cells, and the titers produced by HEK293 cells triple-transfected with pHelper (6234, Clontech), pLMC31, and pLMC32-35 were significantly higher in HEK293 cells triple-transfected with Clontech vectors (pHelper (6234, Clontech)), pRC2-mi342 (6234, Clontech), and pAAV-GFP (AAV-400, Cell Biolabs). [Figure 21] FIG. 21 shows the primer sequences (SEQ ID NOs: 43 to 74, respectively, in the order shown) used in the TaqMan-qPCR and genomic DNA PCR analyses. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0020] [Detailed Description of the Invention]

[0040] The use of the words "a" or "an," when used in connection with the term "comprising" in the claims and / or specification, may mean "one," but is also consistent with meaning "one or more," "at least one," and "one or more."

[0021]

[0041] The term "about" is used herein to indicate that a value has an inherent error variation in the method / device used to measure the value or that such variation exists in the test subject. Typically, the term is meant to include a variability of approximately 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20%, or less, depending on the context.

[0022]

[0042] The use of the term "or" in the claims is intended to mean "and / or" unless expressly indicated to be a mere alternative or intended to not exclusively include such alternatives, although support is provided in the present disclosure for such alternatives and definitions related to "and / or."

[0023]

[0043] As used in the specification and claim(s), the words "comprising" (and any synonyms, e.g., "comprise" and "comprises"), "having" (and any synonyms, e.g., "have" and "has"), "including" (and any synonyms, e.g., "includes" and "include") or "containing" (and any synonyms, e.g., "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. It is contemplated that any embodiment described herein can be implemented with respect to any method, system, host cell, expression vector and / or composition of the invention. Furthermore, the compositions, systems, cells and / or vectors of the invention can be used to practice any of the methods described herein.

[0024]

[0044] The use of the term "for example" and its corresponding abbreviation "eg" (whether italicized or not) means that the specific terms being described are representative examples and embodiments of the disclosure and are not limited to the specific examples referenced or cited, unless specifically stated otherwise.

[0025]

[0045] The present disclosure provides a mammalian cell comprising: (i) at least four distinct recombination target sites (RTS); (ii) adenovirus (Ad) genes including E1A, E1B or a combination thereof; and (iii) a promoter operably linked to the Ad genes, wherein the RTS, Ad genes and promoter are integrated into a chromosome.

[0026]

[0046] "Nucleic acid", "nucleic acid molecule" or "oligonucleotide" refers to a polymeric compound containing covalently linked nucleotides. The term "nucleic acid" includes polyribonucleic acid (RNA) and polydeoxyribonucleic acid (DNA), either of which may be single-stranded or double-stranded. DNA includes, but is not limited to, complementary DNA (cDNA), genomic DNA, plasmid or vector DNA, and synthetic DNA. RNA includes, but is not limited to, mRNA, tRNA, rRNA, snRNA, microRNA, miRNA, or MIRNA.

[0027]

[0047] The term "recombinant," when used in reference to a nucleic acid molecule, peptide, polypeptide, or protein, refers to a novel combination of genetic material not known to occur in nature, or the result thereof. Recombinant molecules can be prepared by any of the well-known techniques available in the field of recombinant technology, including, but not limited to, polymerase chain reaction (PCR), genetic cleavage (e.g., using restriction endonucleases), and solid phase synthesis of nucleic acid molecules, peptides, or proteins. In some embodiments, "recombinant" refers to a viral vector or virus that is not known to occur in nature, for example, a viral vector or virus that has one or more mutations, nucleic acid insertions, or heterologous genes in the viral vector or virus. In some embodiments, "recombinant" refers to a cell or host cell that is not known to occur in nature, for example, a cell or host cell that has one or more mutations, nucleic acid insertions, or heterologous genes in the cell or host cell.

[0028]

[0048] An "isolated" polypeptide, protein, peptide, or nucleic acid is a molecule that has been removed from its natural environment. An "isolated" polypeptide, protein, peptide, or nucleic acid may be prepared with an excipient (e.g., a diluent or adjuvant) and still be considered isolated.

[0029]

[0049] The term "sequence identity" or "% identity" in the context of nucleic acid or amino acid sequences refers to the percentage of residues in the compared sequences that are identical when the sequences are aligned over a specified comparison window. The comparison window can be a segment of at least 10 to 1000 or more residues over which sequences can be aligned and compared. Alignment methods for determining sequence identity are well known in the art and can be performed using publicly available databases, such as BLAST (blast.ncbi.nlm.nih.gov / Blast.cgi.).

[0030]

[0050] In some embodiments, a polypeptide or nucleic acid molecule has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to a reference polypeptide or nucleic acid molecule (or a fragment of a reference polypeptide or nucleic acid molecule), respectively. In certain embodiments of the present disclosure, a polypeptide or nucleic acid molecule has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99% or 100% sequence identity to a reference polypeptide or nucleic acid molecule (or a fragment of a reference polypeptide or nucleic acid molecule), respectively. In some embodiments, a polypeptide or nucleic acid molecule has about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% sequence identity to a reference polypeptide or nucleic acid molecule, respectively.

[0031]

[0051] As used herein, a "promoter", "promoter sequence" or "promoter region" refers to a DNA control region / sequence that can bind RNA polymerase and is involved in initiating transcription of downstream coding or non-coding sequences. In some examples of the present disclosure, the promoter sequence includes a transcription start site and includes the minimum bases or elements upstream necessary to initiate transcription at a detectable level above background. In some embodiments, the promoter sequence includes a transcription start site and a protein binding domain that serves to bind RNA polymerase. Eukaryotic promoters often, but not always, include a "TATA" box and a "CAT" box. A variety of promoters, including inducible promoters, may be used to drive gene expression, for example, in the host cells or vectors of the present disclosure. In some embodiments, the promoter is not a promoter that results in leak expression, i.e., the promoter does not constitutively express any one of the gene products described herein.

[0032]

[0052] As used herein, the term "mammalian cell" includes cells derived from any member of the mammalian class (e.g., human cells, mouse cells, rat cells, monkey cells, hamster cells, and others). In some embodiments, the cell is a mouse cell, a human cell, a Chinese Hamster Ovary (CHO) cell, a CHO-K1 cell, a CHO-DXB11 cell, a CHO-DG44 cell, a CHOK1SV™ cell including all variants (e.g., CHOK1SV POTELLIGENT™, Lonza, Slough, UK), a CHOK1SV GS-KO™ cell including all variants (XCeed™, Lonza, Slough, UK), a HEK293 cell including adherent and suspension adapted variants, a HeLa cell, or a HT1080 cell.

[0033]

[0053] The term "chromosomally integrated" or "chromosomal integration" as used herein refers to the stable incorporation of a nucleic acid sequence into a chromosome of a host cell (e.g., a mammalian cell), i.e., the nucleic acid sequence is integrated into the genomic DNA (gDNA) of a chromosome of a host cell (e.g., a mammalian cell). In some embodiments, the nucleic acid sequence integrated into a chromosome is stable. In some embodiments, the nucleic acid sequence integrated into a chromosome is not located on a plasmid or vector. In some embodiments, the nucleic acid sequence integrated into a chromosome is not excised. In some embodiments, the integration into a chromosome is mediated by a clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated proteins (Cas) gene editing system (CRISPR / CAS).

[0034]

[0054] As used herein, the terms "recombinant target site-specific integration" or "site-specific integration" are interchangeable and can be used to introduce one or more genes into a host cell chromosome. See Bode et al., Biol. Chem. 381:801-813(2000), Kolb, Cloning and Stem Cells 4:381-392(2002) and Coates et al., Trends in Biotech. 23:407-419(2005), which are incorporated herein by reference. In some embodiments, "recombinant target site-specific integration" or "site-specific integration" refers to the integration of a nucleic acid sequence into a specific site in a chromosome. In some embodiments, the site-specific integration is achieved by site-specific recombination. In some embodiments, "site-specific recombination" refers to the reorganization of two DNA partner molecules by specific enzymes that catalyze the recombination of sequences or target sites with their cognate pairs. In contrast to homologous recombination, site-specific recombination and site-specific integration require only slight DNA homology between partner DNA molecules, are independent of RecA, and do not involve DNA replication at any stage. In some embodiments, site-specific recombination uses a site-specific recombinase system that catalyzes the site-specific integration of nucleic acids in a host cell (e.g., a mammalian cell). A recombinase system typically consists of three elements: two specific DNA sequences (recombination target sites) and a specific enzyme (recombinase). The recombinase catalyzes the recombination reaction between multiple specific recombination target sites.

[0035]

[0055] Other means known to those skilled in the art may be used to insert one or more of the desired nucleic acid sequences (e.g., genes). In some embodiments, one or more of the nucleic acid sequences (e.g., genes) are inserted into a chromosome using homologous recombination. "Homologous recombination" refers to genetic recombination in which nucleotide sequences are exchanged between two similar or identical DNA molecules. In some embodiments, a region (e.g., a gene) targeted for deletion / insertion is deleted / inserted by homologous recombination. For example, a DNA construct is used that contains an incoming sequence with a selectable marker flanked by sequences that have homology to the region targeted for deletion / insertion. The DNA construct is aligned with the homologous sequence of the host chromosome, and in a double crossover event, the targeted region is either (i) excised from the host chromosome or (ii) inserted into the chromosome. In some embodiments, homologous recombination is not used to insert a recombination target site, an adenovirus (Ad) gene (e.g., E1A, E1B, E2A, E4, VA, MIR342, or a combination thereof), and / or a promoter operably linked to an Ad gene.

[0036]

[0056] Recombinase enzymes or recombinases are specific enzymes that catalyze recombination in site-specific recombination. In some embodiments of the present disclosure, the recombinase used in site-specific recombination is derived from a non-mammalian system. In some embodiments, the recombinase is derived from bacteria, bacteriophage, or yeast.

[0037]

[0057] In some embodiments, the nucleic acid sequence encoding the recombinase is integrated into a host cell (e.g., a mammalian cell). In some embodiments, the nucleic acid sequence encoding the recombinase is delivered to the host cell by other methods known in molecular biology. In some embodiments, the polypeptide sequence of the recombinase may be delivered directly to the cell. In some embodiments, the recombinase is Cre recombinase, Dre recombinase, KD recombinase, B2B3 recombinase, Hin recombinase, Tre recombinase, λ integrase, HK022 integrase, HP1 integrase, γδ resolvase / invertase, ParA resolvase / invertase, Tn3 resolvase / invertase, Gin resolvase / invertase, φC31 integrase, BxB1 integrase, R4 integrase, or other functional recombinase enzyme. For example, Thorpe & Smith, Proc. Nat'l. Acad. Sci. USA 95: 5505-5510 (1998), Kuhstoss & Rao, J. Mol. Biol. 222:897-890 (1991), U.S. Patent No. 5,190,871, Ow & Ausubel, J. Bacteriol. 155:704-713(1983), Matsuura et al., J. Bacteriol. 178:3374-3376(1996), Sato et al., J. Bacteriol. 172:1092-1098(1990), Stragier et al., Science 243:507-512(1989), Carrasco et al., Genes Dev. 8: 74-83 (1994), Bannam et al., Mol. Microbiol. 16:535-551 (1995), Crelin & Rood, J. Bacteriol. 179:5148-5156 (1997).

[0038]

[0058] In some embodiments, the recombinase described herein is an FLP recombinase. The FLP recombinase is a protein that catalyzes a site-specific recombination reaction involved in amplifying the copy number of the 2 μm plasmid of Saccharomyces cerevisiae during DNA replication. In some embodiments, the FLP recombinase of the present disclosure is derived from a species of the genus Saccharomyces. In some embodiments, the FLP recombinase is derived from Saccharomyces cerevisiae. In some embodiments, the FLP recombinase is derived from a strain of Saccharomyces cerevisiae. In some embodiments, the FLP recombinase is a thermostable mutant FLP recombinase. In some embodiments, the FLP recombinase is FLP1 or FLPe. In some embodiments, the nucleic acid sequence encoding the FLP recombinase comprises human-optimized codons.

[0039]

[0059] In some embodiments, the recombinase is a Cre recombinase. Cre (causes recombination) is a member of the Int family of recombinases (Argos et al. (1986) EMBO J. 5:433) and has been shown to perform efficient recombination of locus of X-ing over in bacteria as well as in eukaryotic cells (Sauer (1987) Mol. Cell. Biol. 7:2087; Sauer and Henderson (1988) Proc. Natl Acad. Sci. 85:5166). In some embodiments, the Cre recombinase described and used herein is derived from a bacteriophage. In some embodiments, the Cre recombinase is derived from P1 bacteriophage.

[0040]

[0060] The terms "recombination target site", "RTS" and "site-specific recombinase target site" as used herein refer to a short (e.g., less than 60 base pairs) nucleic acid site or sequence that is recognized by a site-specific recombinase and becomes the crossover region during a site-specific recombination event. The acronym "RTS" refers to either a single recombination target site or multiple recombination target sites. In some embodiments, the RTS is less than about 60 base pairs, less than about 55 base pairs, less than about 50 base pairs, less than about 45 base pairs, less than about 40 base pairs, less than about 35 base pairs, or less than about 30 base pairs. In some embodiments, the RTS is about 30 to about 60 base pairs, about 30 to about 55 base pairs, about 32 to about 52 base pairs, about 34 to about 44 base pairs, about 32 base pairs, about 34 base pairs, or about 52 base pairs. Examples of RTS include, but are not limited to, lox sites, rox sites, Frt sites, att sites, and dif sites. In some embodiments, the RTS is a nucleic acid having substantially the same sequence as a sequence shown in any of Tables 1, 2, 3, or 4.

[0041]

[0061] In some embodiments, the RTS is a lox site selected from Table 1. The term "lox site" as used herein refers to a nucleotide sequence at which Cre recombinase can catalyze site-specific recombination. A variety of non-identical lox sites are known in the art. The sequences of the various lox sites are similar in that they all contain identical 13 base pair inverted repeat sequences flanking an 8 base pair asymmetric core region where recombination occurs. It is the asymmetric core region that is responsible for the orientation of the site and the variability of the various lox sites. Non-limiting examples of these include the naturally occurring loxP (sequence present in the P1 genome), loxB, loxL and loxR (which are present in the E. coli chromosome), as well as several mutant or modified lox sites (e.g., loxP511, loxΔ86, loxΔ117, loxC2, loxP2, loxP3, loxP23, loxC2, loxP2 and loxP3). In some embodiments, the RTS is a lox site selected from loxΔ86, loxΔ117, loxC2, loxP2, loxP3, and loxP23. In some embodiments, the lox RTS is a nucleic acid having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a sequence shown in Table 1.

[0042] [Table 1]

[0043]

[0062] In some embodiments, the RTS is a Frt site selected from Table 2. The term "Frt site" as used herein refers to a nucleotide sequence in which the product of the FLP gene of the yeast 2 μm plasmid (FLP recombinase) can catalyze site-specific recombination. A variety of non-identical Frt sites are known in the art. The sequences of the various Frt sites are similar in that they all contain identical 13 base pair inverted repeat sequences flanking an 8 base pair asymmetric core region where recombination occurs. It is the asymmetric core region that is responsible for the orientation of the site and the variability of the various Frt sites. These (non-limiting) examples include naturally occurring Frt and some mutant or modified Frt sites (e.g., Frt1, Frt2). In some embodiments, the RTS is a Frt site selected from Frt(F), Frt F1(F1), Frt F2(F2), Frt F3(F3), Frt F4(F4) or Frt F5(F5). In some embodiments, the RTS is a Frt site selected from Frt F6 (F6), Frt F7 (F7), Frt F14 (F14), Frt F15 (F15), or Ff61. In some embodiments, the RTS is a Frt site selected from F2151, Fw2, F2161, and F2262. In some embodiments, the Frt recombination target site is a nucleic acid having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a sequence set forth in Table 2.

[0044] [Table 2]

[0045]

[0063] In some embodiments, the RTS is a rox site selected from Table 3. As used herein, the term "rox site" refers to a nucleotide sequence at which Dre recombinase can catalyze site-specific recombination. A variety of non-identical rox sites are known in the art. Non-limiting examples of these include roxR and roxF. In some embodiments, the rox recombination target site is a nucleic acid having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a sequence shown in Table 3.

[0046] [Table 3]

[0047]

[0064] In some embodiments, the RTS is an att site selected from Table 4. As used herein, the term "att site" refers to a nucleotide sequence at which lambda integrase or φC31 integrase can catalyze site-specific recombination. A variety of non-identical att sites are known in the art. Non-limiting examples of these include attP, attB, proB, trpC, galT, thrA, and rrnB. In some embodiments, the att recombination target site is a nucleic acid having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a sequence shown in Table 4.

[0048] [Table 4]

[0049]

[0065] The term "distinct recombination target sites" as used herein refers to non-identical or heterospecific recombination target sites. For example, although some variant Frt sites exist, recombination can usually only occur between two identical Frt sites. In some embodiments, distinct recombination target sites refer to non-identical recombination target sites that are derived from the same recombination system (e.g., LoxP and LoxR). In some embodiments, distinct recombination target sites refer to non-identical recombination target sites that are derived from different recombination systems (e.g., LoxP and Frt). In some embodiments, distinct recombination target sites refer to a combination of recombination target sites that are derived from the same recombination system and recombination target sites that are derived from different recombination systems (e.g., LoxP, LoxR, Frt, and Frt1).

[0050]

[0066] Various combinations of RTSs can be used. In some embodiments, the cell comprises four RTSs. In some embodiments, the cell comprises six RTSs. In some embodiments, at least one RTS is selected from SEQ ID NOs: 1-30. In some embodiments, at least one RTS is selected from SEQ ID NOs: 1-6. In some embodiments, at least one RTS is selected from SEQ ID NOs: 28-30. In some embodiments, at least one RTS is selected from SEQ ID NOs: 7-21. In some embodiments, at least one RTS is selected from SEQ ID NOs: 22-23. In some embodiments, at least one RTS is selected from SEQ ID NOs: 24-27. In some embodiments, at least one RTS is selected from SEQ ID NOs: 28-30. In some embodiments, the cell comprises at least four distinct RTSs comprising the following RTSs: LoxP_511, Frt_F5, Frt and LoxP. In some embodiments, the cell comprises at least four distinct RTSs comprising the following RTSs: Frt_F14 and Frt_F15. In some embodiments, a cell comprising at least four distinct RTSs comprises the following RTSs: LoxP_511, Frt_F5, Frt, LoxP, Frt_F14 and Frt_F15. In some embodiments, a cell comprising at least four distinct RTSs may comprise the following RTSs: Frt_1, Frt_2, Frt_3, Frt_4. In some embodiments, a cell comprising at least four distinct RTSs comprises the following RTSs: Frt_m5, Frt_wt, Frt_m14, Frt_m15, Frt_m7 and Frt_m6.

[0051]

[0067] The term "landing pad" as used herein refers to a nucleic acid sequence that comprises a first recombination target site that is integrated into a chromosome in a host cell. In some embodiments, the landing site comprises two or more recombination target sites that are integrated into a chromosome in a host cell. In some embodiments, the cell comprises 1, 2, 3, 4, 5, 6, 7, or 8 landing pads. In some embodiments, the landing pads are integrated into up to 1, 2, 3, 4, 5, 6, 7, or 8 separate chromosomal loci.

[0052]

[0068] The term "adenovirus" as used herein refers to a non-enveloped virus of the Adenoviridae family, which has an icosahedral nucleocapsid containing double-stranded DNA. More than 50 subtypes of adenovirus have been isolated from humans, and many additional subtypes have been isolated from other mammals and birds. Birds. See, for example, Ishibashi et al., "Adenoviruses of animals," In The Adenoviruses, Ginsberg, ed., Plenum Press, New York, NY, pp. 497-562(1984); Strauss, "Adenovirus infections in humans," In The Adenoviruses, Ginsberg, ed., Plenum Press, New York, NY, pp.451-596(1984). These subtypes belong to the Adenoviridae family, which is currently divided into two genera, namely Mastadenovirus and Aviadenovirus. All adenoviruses are morphologically and structurally similar. However, in humans, adenoviruses exhibit different immunological properties, i.e., they are classified into serotypes. Two human serotypes of adenoviruses (i.e., Ad2 and Ad5) have been extensively studied, providing a wealth of general information about adenoviruses.

[0053]

[0069] "Gene" refers to a collection of nucleotides that encodes a polypeptide, and includes nucleic acid molecules that are cDNA and genomic DNA. "Gene" may also refer to a nucleic acid fragment that can act as a regulatory sequence preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. In some embodiments, the gene is integrated in multiple copies. In some embodiments, the gene is integrated in a predetermined copy number.

[0054]

[0070] The term "adenovirus gene" or "AV gene" as used herein refers to a gene composed of one or more nucleic acid sequences derived from one or more adenovirus subtypes or serotypes. In some embodiments, the Ad gene is a gene involved in the replication and packaging of adeno-associated virus. In some embodiments, the Ad gene is E1A, E1B, E2A, E4, VA, MIR342, or a combination thereof, or any other Ad gene. In some embodiments, the disclosure provides a cell in which one or more of the Ad genes are chromosomally integrated in the cell. In some embodiments, the disclosure provides a cell in which one or more of E1A, E1B, E2A, E4, VA, MIR342 are chromosomally integrated in the cell. In some embodiments, the Ad gene includes E1A. In some embodiments, the Ad gene includes E1A and E1B. In some embodiments, the Ad gene includes E1A, E1B, and E2A. In some embodiments, the Ad gene includes E1A, E1B, E2A, and E4. In some embodiments, the Ad genes include E1A, E1B, E2A, E4, and VA. In some embodiments, the Ad genes include E1A, E1B, E2A, E4, VA, and MIR342. In some embodiments, the Ad genes include E1A and E2A. In some embodiments, the Ad genes include E1A, E2A, and E4. In some embodiments, the Ad genes include E1A, E2A, E4, and VA. In some embodiments, the Ad genes include E1A, E2A, E4, VA, and MIR342. In some embodiments, the Ad genes include E1A and E4. In some embodiments, the Ad genes include E1A, E4, and VA. In some embodiments, the Ad genes include E1A, E4, VA, and MIR342. In some embodiments, the Ad genes include E1A and VA. In some embodiments, the Ad genes include E1A, VA, and MIR342. In some embodiments, the Ad genes include E1A and VA. In some embodiments, the Ad genes include E1A, VA, and MIR342. In some embodiments, the Ad genes include E1A and VA. In some embodiments, the Ad genes include E1A, VA, and MIR342. In some embodiments, the Ad genes include E1A and MIR342. In some embodiments, the Ad genes include E1B. In some embodiments, the Ad genes include E1B and E2A, In some embodiments, the Ad genes include E1B, E2A, and E4.In some embodiments, the Ad genes include E1B, E2A, E4, and VA. In some embodiments, the Ad genes include E1B, E2A, E4, VA, and MIR342. In some embodiments, the Ad genes include E1B and E4. In some embodiments, the Ad genes include E1B, E4, and VA. In some embodiments, the Ad genes include E1B, E4, VA, and MIR342. In some embodiments, the Ad genes include E1B and VA. In some embodiments, the Ad genes include E1B, VA, and MIR342. In some embodiments, the Ad genes include E1B and VA. In some embodiments, the Ad genes include E1B, VA, and MIR342. In some embodiments, the Ad genes include E1B and MR342. In some embodiments, the Ad genes include E2A. In some embodiments, the Ad genes include E2A and E4. In some embodiments, the Ad genes include E2A, E4, and VA. In some embodiments, the Ad genes include E2A, E4, VA, and MIR342. In some embodiments, the Ad genes include E2A and VA. In some embodiments, the Ad genes include E2A, E4, VA, and MIR342. In some embodiments, the Ad genes include E2A and VA. In some embodiments, the Ad genes include E2A, VA, and MIR342. In some embodiments, the Ad genes include E2A and MIR342. In some embodiments, the Ad genes include E4. In some embodiments, the Ad genes include E4 and VA. In some embodiments, the Ad genes include E4, VA and MIR342. In some embodiments, the Ad genes include E4 and MIR342. In some embodiments, the Ad genes include VA. In some embodiments, the Ad genes include VA and MIR342. In some embodiments, the Ad genes include MIR342. In some embodiments, the inventors have found that when the Ad genes include E1A, E1B, E2A, E4, VA and MIR342, the Ad genes are integrated into the chromosome and more consistent Ad gene expression is observed. In some embodiments, the Ad genes include one or more selected from E1A, E1B, E2A, E4, VA and MIR342.

[0055]

[0071] The term "control element" as described herein refers to a genetic element that controls some aspect of the expression of a nucleic acid sequence. As used herein, a "promoter" is a control element that facilitates the initiation of transcription of an operably linked coding region. In some embodiments, the promoter is an Ad promoter. As used herein, the term "AV promoter" refers to such a control element derived from an adenovirus system. In some embodiments, the promoter is an AAV promoter. As used herein, the term "AAV promoter" refers to such a control element derived from an adeno-associated virus system. In some embodiments, the present disclosure provides a cell in which one or more of the AAV promoters are integrated into a chromosome in the cell. As used herein, the term "non-AV promoter" refers to such a control element derived from a non-adenovirus system. In some embodiments, the non-AV promoter is derived from a prokaryotic system. In some embodiments, the non-AV promoter is derived from a eukaryotic system. In some embodiments, the present disclosure provides a cell in which one or more of the promoters are integrated into a chromosome in the cell. In some embodiments, the present disclosure provides a cell in which one or more of the non-Ad promoters are integrated into a chromosome in the cell. In some embodiments, the present disclosure provides a cell in which one or more of the Ad promoters are integrated into a chromosome in the cell. In some embodiments, the promoter is a non-AAV promoter. The term "non-AAV promoter" as used herein refers to such a control element that is not derived from the system of adeno-associated virus. In some embodiments, the non-AAV promoter is derived from a prokaryotic system. In some embodiments, the non-AAV promoter is derived from a eukaryotic system. In some embodiments, the present disclosure provides a cell in which one or more of the non-AAV promoters are integrated into a chromosome in the cell.

[0056]

[0072] The terms "in operable combination," "in operable order," and "operably linked" as used herein refer to the association of nucleic acid sequences in such a way that a nucleic acid molecule capable of directing transcription of a given gene and / or synthesis of a desired protein molecule is produced. The terms may also refer to the association of amino acid sequences in such a way that a functional protein is obtained. In some embodiments, the Ad gene is operably linked to a promoter and the Ad gene is integrated into the chromosomal genome of the host cell. In some embodiments, the Ad gene is operably linked to a non-Ad promoter and the Ad gene is integrated into the chromosomal genome of the host cell. In some embodiments, the Ad gene is operably linked to an Ad promoter and the Ad gene is integrated into the chromosomal genome of the host cell. In some embodiments, the AAV gene is operably linked to a promoter and the AAV gene is integrated into the chromosomal genome of the host cell. In some embodiments, the AAV gene is operably linked to a non-AAV promoter and the AAV gene is integrated into the chromosomal genome of the host cell. In some embodiments, the AAV gene is operably linked to an AAV promoter and the AAV gene is integrated into the chromosomal genome of the host cell. In some embodiments, the GOI gene is operably linked to a promoter and the GOI gene is integrated into the genome of a chromosome of the host cell. In some embodiments, the GOI gene is operably linked to a non-GOI promoter and the GOI gene is integrated into the genome of a chromosome of the host cell. In some embodiments, the recombinase gene is operably linked to a promoter and the recombinase gene is integrated into the genome of a chromosome of the host cell. In some embodiments, the recombinase gene is operably linked to a promoter and the recombinase gene is integrated into the genome of a chromosome of the host cell. In some embodiments, the recombinase gene is operably linked to a promoter and the recombinase gene is not integrated into the genome of a chromosome of the host cell. In some embodiments, the recombinase gene is operably linked to a promoter and the recombinase gene is not integrated into the genome of a chromosome of the host cell.

[0057]

[0073] In some embodiments, the control element operably links gene expression to the presence of an exogenously supplied ligand. In some embodiments, the Ad gene is operably linked to a promoter, the promoter operably links gene expression to the presence of an exogenously supplied ligand, and the Ad gene is integrated into the genome of a chromosome of the host cell. In some embodiments, the AAV gene is operably linked to a promoter, the promoter operably links gene expression to the presence of an exogenously supplied ligand, and the AAV gene is integrated into the genome of a chromosome of the host cell. In some embodiments, the GOI is operably linked to a promoter, the promoter operably links gene expression to the presence of an exogenously supplied ligand, and the GOI is integrated into the genome of a chromosome of the host cell. In some embodiments, the recombinase gene is operably linked to a promoter, the promoter operably links gene expression to the presence of an exogenously supplied ligand, and the recombinase gene is integrated into the genome of a chromosome of the host cell. In some embodiments, the recombinase gene is operably linked to a promoter, the promoter operably links gene expression to the presence of an exogenously supplied ligand, and the recombinase gene is not integrated into the genome of the host cell chromosome. In some embodiments, the E1A expression is operably linked to a promoter, the promoter operably links gene expression to the production of rAAV. In some embodiments, the E1A expression is operably linked to a promoter, the promoter operably links gene expression to the presence of an exogenously supplied ligand, and the gene expression operably links the presence of an exogenously supplied ligand to the production of rAAV.

[0058]

[0074] In some embodiments, at least one RTS, Ad gene, and promoter are integrated at a single chromosomal locus. In some embodiments, the first Ad genes E1A and E1B, and the second Ad genes including E2A, E4, VA, and MIR342 are at two different loci. In some embodiments, the first Ad genes E1A and E1B, and the second Ad genes including E2A, E4, VA, and MIR342 are at the same locus. In some embodiments, the first Ad genes E1A and E1B, and the second Ad genes including E2A, E4, VA, and MIR342 are at the same locus, and the adeno-associated virus (AAV) genes are at a different locus. In some embodiments, the first Ad genes E1A and E1B, and the second Ad genes including E2A, E4, VA, and MIR342 are at the same locus, and the adeno-associated virus (AAV) genes and the AAV vector cassette are at different loci.

[0059]

[0075] The term "chromosomal locus" as used herein refers to a predetermined location of a nucleic acid on a chromosome of a cell, which may include at least one gene. In some embodiments, the chromosomal locus is about 500 base pairs to about 100,000 base pairs, about 5,000 base pairs to about 75,000 base pairs, about 5,000 base pairs to about 60,000 base pairs, about 20,000 base pairs to about 50,000 base pairs, about 30,000 base pairs to about 50,000 base pairs, or about 45,000 base pairs to about 49,000 base pairs. In some embodiments, the chromosomal locus extends up to about 100 base pairs, about 250 base pairs, about 500 base pairs, about 750 base pairs, or about 1000 base pairs from the 5' or 3' end of the predetermined nucleic acid sequence. In some embodiments, the chromosomal locus comprises an endogenous nucleic acid sequence. In some embodiments, the chromosomal locus comprises an exogenous nucleotide sequence integrated into the chromosome using methods known to those skilled in the art of molecular biology. In some embodiments, the chromosomal locus comprises a nucleotide sequence that provides strong and stable production in the genome of the host cell of a protein encoded by a gene integrated into the chromosomal locus. In some embodiments, the chromosomal locus comprises a nucleotide sequence that provides strong and stable expression in the genome of the host cell of a viral gene. In some embodiments, the chromosomal locus comprises a nucleotide sequence that provides efficient site-specific recombination in the genome of the host cell. In some embodiments, the chromosomal locus comprises Fer1L4 (see, e.g., U.S. Patent Application Serial No. 14 / 409,283), ROSA26, HGPRT, DHFR, COSMC, LDHA, or MGAT1. In some embodiments, the chromosomal locus comprises NL1 or NL2. In some embodiments, the chromosomal locus comprises the first intron of MID1 on the X chromosome. In some embodiments, the chromosomal locus is an expression enhancing and stability region (Regeneron, Tarrytown, NY, EESYR; see, e.g., U.S. Pat. No. 7,771,997). In some embodiments, at least a portion of the nucleic acid of the chromosomal locus is deleted.

[0060]

[0076] In some embodiments, the chromosomal locus comprises the NL1 locus, NL2 locus, NL3 locus, NL4 locus, NL5 locus, or NL6 locus as set forth in Table A. In some embodiments, the disclosure relates to a mammalian cell comprising at least two distinct recombination target sites (RTS), wherein at least one RTS, an Ad gene, and a promoter are integrated within the NL1 locus, NL2 locus, NL3 locus, NL4 locus, NL5 locus, or NL6 locus. In some embodiments, the first Ad genes, E1A and E1B, and the second Ad genes, including E2A, E4, VA, and MIR342, are at two different loci, one of which is within the NL1 locus, NL2 locus, NL3 locus, NL4 locus, NL5 locus, or NL6 locus. In some embodiments, the first Ad genes E1A and E1B, and the second Ad genes comprising E2A, E4, VA, and MIR342 are located at the NL1 locus, NL2 locus, NL3 locus, NL4 locus, NL5 locus, or NL6 locus. In some embodiments, the first Ad genes E1A and E1B, and the second Ad genes comprising E2A, E4, VA, and MIR342 are located at the NL1 locus, NL2 locus, NL3 locus, NL4 locus, NL5 locus, or NL6 locus. In some embodiments, the first Ad genes E1A and E1B, and the second Ad genes comprising E2A, E4, VA, and MIR342 are located at the NL1 locus, NL2 locus, NL3 locus, NL4 locus, NL5 locus, or NL6 locus. In some embodiments, the disclosure relates to a mammalian cell comprising at least three distinct recombination target sites (RTS), where at least one RTS, Ad gene and promoter is integrated within the NL1 locus, NL2 locus, NL3 locus, NL4 locus, NL5 locus or NL6 locus. In some embodiments, the disclosure relates to a mammalian cell comprising at least four distinct recombination target sites (RTS), where at least one RTS, Ad gene and promoter is integrated within the NL1 locus, NL2 locus, NL3 locus, NL4 locus, NL5 locus or NL6 locus. In some embodiments, the disclosure relates to a mammalian cell comprising at least five distinct recombination target sites (RTS), where at least one RTS, Ad gene and promoter is integrated within the NL1 locus, NL2 locus, NL3 locus, NL4 locus, NL5 locus or NL6 locus.In some embodiments, the disclosure relates to a mammalian cell comprising at least six distinct recombination target sites (RTS), wherein at least one of the RTS, an Ad gene and a promoter is integrated within the NL1 locus, NL2 locus, NL3 locus, NL4 locus, NL5 locus or NL6 locus.

[0061] [Table 5] TIFF0007637470000006.tif226149

[0062]

[0077] One of skill in the art will understand that the term "integrated within the NL1 locus" or "integrated within the NL2 locus" encompasses integration anywhere within the locus and is not limited to only the genomic coordinates indicated. One of skill in the art will understand that the term "integrated within the NL1 locus" or "integrated within the NL2 locus" also encompasses the corresponding locus in the corresponding organism. Thus, in some embodiments, the term "integrated within the NL1 locus" or "integrated within the NL2 locus" will encompass integration within about 50,000 bp, about 40,000 bp, about 30,000 bp, about 20,000 bp, or about 10,000 bp of the indicated genomic coordinates.

[0063]

[0078] In some embodiments, the cell comprises a site-specific recombinase gene. In some embodiments, the site-specific recombinase gene is integrated into a chromosome.

[0064]

[0079] The term "located between two RTSs" as used herein refers to a gene located between two RTSs, i.e., one RTS is located 5' of the gene and another RTS is located 3' of the gene. In some embodiments, the RTSs are located directly adjacent to the gene located between them. In some embodiments, the RTSs are located at a predetermined distance from the gene located between them. In some embodiments, the RTSs are directional sequences. In some embodiments, the 5' and 3' of the gene located between the RTSs are oriented in a forward direction (i.e., they are oriented in the same direction). In some embodiments, the 5' and 3' of the gene located between the RTSs are oriented in a reverse direction (i.e., they are oriented in different directions).

[0065]

[0080] In some embodiments, the cell further comprises adeno-associated virus (AAV) genes, said AAV genes being integrated into the chromosome. The AAV genes comprise any gene from any AAV serotype. In some embodiments, the AAV genes are Rep, Rep78, Rep68, Rep52, Rep40, Cap, VP1, VP2, VP3 or combinations thereof. In some embodiments, the AAV genes are from adeno-associated virus type 2. In some embodiments, the AAV genes are from adeno-associated virus Anc80. In some embodiments, the AAV genes comprise ANC80 Rep and Cap genes. In some embodiments, the AAV genes are located between two RTSs.

[0066]

[0081] The term "adeno-associated virus (AAV)" as used herein refers to a small, replication-defective, non-enveloped virus of the Parvoviridae and Dependoparvovirus families, which contains single-stranded DNA. More than 10 adeno-associated virus serotypes have been identified to date, with serotype AAV2 being the best characterized. Other (non-limiting) examples of AAV serotypes are ANC80, AAV1, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, and AAV11. In addition to these serotypes, AAV pseudotypes have been developed. AAV pseudotypes contain a capsid of a first serotype and a genome of a second serotype (e.g., pseudotype AAV2 / 5 corresponds to an AAV with a genome of serotype AAV2 and a capsid of AAV5).

[0067]

[0082] As used herein, the term "recombinant AAV" or "rAAV" refers to an infectious, replication-defective virus that contains an AAV protein shell that encapsidates (i.e., surrounds with coat protein) a heterologous gene flanked 5' and 3' by AAV ITRs.

[0068]

[0083] As used herein, the term "replication-competent adenovirus (RCA)" refers to an undesirable contaminant of active adenovirus particles that is often produced during rAAV production that results from homologous recombination between a recombinant adenovirus vector and adenovirus genes present in the producer cell genome.

[0069]

[0084] The term "adeno-associated virus gene" as used herein refers to a gene that is composed of one or more nucleic acid sequences derived from one or more adeno-associated virus serotypes. In some embodiments, the AAV gene is a gene involved in AAV replication and packaging.

[0070]

[0085] The term "Rep" gene as described herein refers to the region of the AAV genome that encodes viral replication proteins collectively required for viral genome replication, as known to those skilled in the art, or functional homologs thereof, such as, for example, the human herpesvirus 6 (HHV-6) rep gene (known to mediate AAV-2 DNA replication). Thus, the rep coding region includes at least the AAV Rep78 and Rep68 ("long form Rep") and Rep52 and Rep40 ("short form Rep") encoding genes or functional homologs thereof. For further description of the AAV rep coding region: The rep coding region used in the present invention may be derived from any viral serotype (e.g., the AAV serotypes listed above). The region need not include all wild-type genes, but may be modified (e.g., by nucleotide insertion, deletion, or substitution), so long as the rep gene present exhibits sufficient integration function when expressed in an appropriate target cell. See, e.g., Muzyczka, N., Current Topics in Microbiol. and Immunol. 158:97-129(1992) and Kotin, RM, Human Gene Therapy 5:793-801(1994).

[0071]

[0086] The term "Cap" gene as used herein refers to the region in the AAV genome that encodes viral capsid proteins known to those of skill in the art. Non-limiting examples of these capsid proteins are the AAV capsid proteins VP1, VP2 and VP3. The Cap genes used in this disclosure may be derived from any AAV serotype or combination of AAV serotypes.

[0072]

[0087] In some embodiments, the cell comprises a second Ad gene, the second Ad gene being integrated into the chromosome. In some embodiments, the second Ad gene is E1A, E1B, E2A, E4, VA, MIR342, or a combination thereof. In some embodiments, the second Ad gene is from Ad5. In some embodiments, the second Ad gene is located between two RTSs.

[0073]

[0088] In some embodiments, the cell further comprises an AAV vector cassette, wherein the AAV vector cassette is integrated into the chromosome. In some embodiments, the AAV vector cassette is located between two RTSs.

[0074]

[0089] A "vector" or "expression vector" is a replicon, such as a plasmid, phage, virus, or cosmid, to which another DNA segment is linked, resulting in the replication and / or expression of the linked DNA segment in a cell. "Vector" includes episomal (e.g., plasmid) and non-episomal vectors. In some embodiments of the present disclosure, the vector is an episomal vector, which is removed / lost from the cell population after multiple cell generations, e.g., by asymmetric segregation. The term "vector" encompasses viral and non-viral means for introducing a nucleic acid molecule into a cell in vitro, in vivo, or ex vivo. The term vector may encompass synthetic vectors. Vectors can be introduced into a desired host cell by well-known methods, including, but not limited to, transfection, transduction, cell fusion, and lipofection. Vectors may include various control elements, including promoters.

[0075]

[0090] "Transfection" as used herein means the introduction of an exogenous nucleic acid molecule, including a vector, into a cell. A "transfected" cell contains an exogenous nucleic acid molecule within the cell, and a "transformed" cell is one in which an exogenous nucleic acid molecule within the cell induces a change in the cell's phenotype. The transfected nucleic acid molecule may be integrated into the host cell's genomic DNA and / or may be maintained extrachromosomally by the cell either transiently or long-term. A host cell or organism that expresses an exogenous nucleic acid molecule or fragment is referred to as a "recombinant," "transformed," or "transgenic" organism. Many transfection techniques are commonly known in the art. See, e.g., Graham et al., Virology, 52:456(1973), Sambrook et al., Molecular Cloning, a laboratory manual, Cold Spring Harbor Laboratories, New York(1989), Davis et al., Basic Methods in Molecular Biology, Elsevier(1986), and Chu et al., Gene 13:197(1981). Using such techniques, one or more exogenous DNA moieties (e.g., AAV vector cassettes, AAV helper constructs and other nucleic acid molecules) can be introduced into a suitable host cell.

[0076]

[0091] As used herein, the term "exchangeable cassette" or "cassette" refers to a type of mobile genetic element that contains genes and recombination sites. In some embodiments, the exchangeable cassette comprises at least two RTSs. In some embodiments, the exchangeable cassette comprises a reporter gene or a selection gene. In some embodiments, the cassette is exchanged by recombinase-mediated cassette-exchange (RMCE).

[0077]

[0092] The term "AAV vector cassette" as used herein refers to a cassette derived from an adeno-associated virus serotype vector that may be deleted in whole or in part from one or more of the AAV wild-type genes, such as the Rep and / or Cap genes, but retains functionally flanking inverted terminal repeat (ITR) sequences.

[0078]

[0093] The term "functionally flanking inverted terminal reports" or "functionally flanking ITRs" as used herein refers to 145 base pair ITR sequences located at the 5' and 3' ends of a gene of interest (GOI) in an AAV vector cassette, the first 125 base pairs of which can form a Y- or T-shaped duplex structure. The ITR sequences represent the minimal sequences required for replication, rescue, packaging and integration of the AAV genome.

[0079]

[0094] As used herein, the terms "auxiliary genes," "helper genes," and "auxiliary helper genes" are used interchangeably to refer to a first gene that assists in the replication or packaging of rAAV. In some embodiments, the helper genes comprise viral genes. In some embodiments, the helper genes comprise Ad genes. In some embodiments, the helper genes comprise AAV genes. In some embodiments, the helper genes comprise AAV genes, Rep, Cap, or combinations thereof. In some embodiments, the helper genes comprise prokaryotic genes. In some embodiments, the helper genes comprise eukaryotic genes. In some embodiments, the helper genes comprise a gene encoding an RNA. In some embodiments, the helper genes comprise an interferon (IFN) antagonist. In some embodiments, the helper genes encode a protein that is a protein kinase R (PKR) inhibitor. In some embodiments, the helper genes comprise a gene encoding an influenza NS1 protein. In some embodiments, the helper genes include genes encoding the vaccinia virus E3L protein (see, e.g., de Vries et al, Gene Ther. 15:545-52, (2008)). In some embodiments, the helper genes encode virally encoded soluble IFN-α / β receptor decoys that counteract the IFN response in infected cells. In some embodiments, the helper genes encode NS1, E3L or similar proteins. In some embodiments, the helper genes encode NS1, E3L or proteins with homologous sequences or motifs.

[0080]

[0095] The term "gene of interest" or "GOI" as used herein is used to describe a heterologous gene. The term "heterologous gene" or "HG" as used herein, when referring to a nucleic acid sequence, such as a coding sequence or a control sequence, refers to a nucleic acid sequence (e.g., a gene) that is not normally associated with and / or is not normally associated with a particular cell. In some embodiments, a heterologous gene is a construct in which the coding sequence itself is not found in nature (e.g., a synthetic sequence with different codons than the native gene). Allelic variation or naturally occurring mutational events do not give rise to heterologous DNA as used in the present invention.

[0081]

[0096] In some embodiments, the gene of interest comprises a reporter gene, a selection gene, a gene of therapeutic interest, or a combination thereof.

[0082]

[0097] As used herein, a "reporter gene" is a gene whose expression confers an easily identifiable and measurable phenotype on a cell. In some embodiments, a reporter gene comprises a fluorescent protein gene. In some embodiments, a reporter gene comprises a selection gene.

[0083]

[0098] The term "selection gene" as used herein refers to the use of a gene encoding an enzymatic activity to confer the ability to grow in a medium lacking a normal essential nutrient, and in addition, the selection gene may be capable of conferring antibiotic or drug resistance to the cells in which the selection gene is expressed. A selection gene may be used to confer a particular phenotype to a host cell. If the host cell must express the selection gene when it is to grow in a selective medium, the gene is called a positive selection gene. A selection gene may also be used to select for host cells that contain a particular gene, and a selection gene used in this way is called a negative selection gene.

[0084]

[0099] The term "therapeutic gene" as used herein refers to any functionally relevant nucleotide sequence. That is, the therapeutic gene of the present disclosure may include any necessary gene encoding a protein that is incomplete or missing in the genome of the target cell, or a gene encoding a non-native protein with a desired biological or therapeutic effect (e.g., antiviral function), or the sequence may correspond to a molecule with antisense or ribozyme function. Representative (non-limiting) examples of suitable therapeutic genes include genes used to treat inflammatory diseases, autoimmune, chronic and infectious diseases (including disorders such as AIDS, cancer, neurological diseases, cardiovascular diseases, hypercholestasia, etc.), various blood diseases such as various anemias, thalassemias, and hemophilias, genetic defects (e.g., cystic fibrosis, Gaucher disease, adenosine deaminase (ADA) deficiency, emphysema, etc.). Several antisense oligonucleotides (e.g., short oligonucleotides complementary to sequences surrounding the translation start site (AUG codon) of mRNA) that are useful in antisense therapy for cancer and for viral diseases have been described in the prior art and are also examples of suitable therapeutic genes.

[0085]

[0100] In some embodiments, the cells are substantially free of helper virus. A "helper virus" as described herein is any non-AAV virus that is added to allow replication and packaging of the adeno-associated virus. Representative (non-limiting) examples of helper viruses are adenovirus and herpes virus. In some embodiments, the term substantially free of helper virus refers to cells with less than 100, less than 10, or less than 1 helper virus per cell. In some embodiments, the term substantially free of helper virus refers to a population of cells in which helper virus is absent or in which helper virus is not detectable using known detection methods. In some embodiments, wild-type helper virus is absent from the cells. In some embodiments, the term "wild-type virus" refers to any complete non-AAV virus that can replicate in a cell independently of any other virus.

[0086]

[0101] In some embodiments, the invention provides a mammalian cell comprising (i) at least four distinct recombination target sites (RTS), (ii) adenovirus (Ad) genes E2A, E4, VA, MIR342, or a combination thereof, and (iii) a promoter operably linked to the Ad genes, wherein the RTS, Ad genes, and promoter are integrated into a chromosome. In some embodiments, the cell is a mouse cell, a human cell, a CHO cell, a CHO-K1 cell, a CHO-DXB11 cell, a CHO-DG44 cell, a CHOK1SV™ cell including all variants (e.g., CHOK1SV™ POTELLIGENT™), a CHOK1SV GS-KO™ cell including all variants (e.g., XCEED™), a HEK293 cell including adherent-adapted and suspension-adapted variants, a HeLa cell, or a HT1080 cell.

[0087]

[0102] In some embodiments, the cell comprises four RTSs. In some embodiments, the cell comprises six RTSs. In some embodiments, at least one RTS is selected from SEQ ID NOs: 1-30. In some embodiments, the RTS, Ad gene and promoter are integrated into a single chromosomal locus. In some embodiments, the chromosomal locus is Fer1L4, ROSA26, HGPRT, DHFR, COSMC, LDHa, MGAT1, GRIK1, NL1, NL2, NL3, NL4, NL5, NL6, the first intron of MID1 on the X chromosome, or the expression enhancing and stability region (EESYR). In some embodiments, the cell comprises a site-specific recombinase gene. In some embodiments, the site-specific recombinase gene is integrated into the chromosome. In some embodiments, the cell further comprises a second Ad gene, and the second Ad gene is integrated into the chromosome. In some embodiments, the second Ad gene comprises E1A, E1B, E2A, E4, VA, MIR342, or a combination thereof. In some embodiments, the second Ad gene is from Ad5. In some embodiments, the second Ad gene is located between two RTSs. In some embodiments, the cell further comprises adeno-associated virus (AAV) genes, and the AAV genes are integrated into the chromosome. In some embodiments, the AAV genes include Rep, Cap, or a combination thereof. In some embodiments, the AAV genes are from adeno-associated virus type 2. In some embodiments, the AAV genes are located between two RTSs. In some embodiments, the cell further comprises an AAV vector cassette, and the AAV vector cassette is integrated into the chromosome. In some embodiments, the AAV vector cassette is a reporter gene, a selection gene, a therapeutic gene, or a combination thereof. In some embodiments, the AAV vector cassette is located between two RTSs. In some embodiments, the cell is substantially free of helper virus.

[0088]

[0103] In some embodiments, the disclosure provides a mammalian cell comprising (i) at least four distinct recombination target sites (RTS) and (ii) adeno-associated virus (AAV) genes including Rep, Cap, or a combination thereof, wherein the RTS and AAV genes are integrated into a chromosome. In some embodiments, the cell is a mouse cell, a human cell, a CHO cell, a CHO-K1 cell, a CHO-DXB11 cell, a CHO-DG44 cell, a CHOK1SV™ cell including all variants (e.g., CHOK1SV™ POTELLIGENT™), a CHOK1SV GS-KO™ cell including all variants, a HEK293 cell including adherent-adapted and suspension-adapted variants, a HeLa cell, or a HT1080 cell. In some embodiments, the cell comprises four RTSs. In some embodiments, the cell comprises six RTSs. In some embodiments, at least one RTS is selected from SEQ ID NOs: 1-30. In some embodiments, the RTS and the AAV are integrated into a single chromosomal locus. In some embodiments, the chromosomal locus is Fer1L4, ROSA26, HGPRT, DHFR, COSMC, LDHa, MGAT1, GRIK1, NL1, NL2, the first intron of MID1 on the X chromosome, or the expression enhancing and stability region (EESYR). In some embodiments, the cell comprises a site-specific recombinase gene. In some embodiments, the site-specific recombinase gene is integrated into the chromosome. In some embodiments, the cell further comprises an Ad gene and a promoter operably linked to the Ad gene, whereby the Ad gene and the promoter are integrated into the chromosome. In some embodiments, the Ad gene comprises E1A, E1B, E2A, E4, VA, MIR342, or a combination thereof. In some embodiments, the Ad gene is from Ad5. In some embodiments, the AAV gene is located between the two RTSs. In some embodiments, the cell further comprises an AAV vector cassette. In some embodiments, the AAV vector cassette comprises a reporter gene, a selection gene, a gene of therapeutic interest, or a combination thereof. In some embodiments, the gene of interest is located between two RTSs.In some embodiments, the cells are substantially free of helper virus, hi some embodiments, the cells are completely free of helper virus.

[0089]

[0104] In some embodiments, the disclosure provides a Chinese hamster ovary (CHO) cell comprising six distinct recombination target sites (RTS), where at least one RTS is selected from the group consisting of SEQ ID NOs: 1-30; an adenovirus (Ad) gene comprising E1A and E1B; and a promoter operably linked to the Ad gene, where the RTS, Ad genes, and promoter are integrated into the chromosome; a second Ad gene comprising E2A, E4, VA, and MIR342, the second Ad gene being located between the two RTSs; an adeno-associated virus (AAV) gene comprising Rep and Cap, the AAV gene being located between the two RTSs; and an AAV vector cassette comprising a reporter gene, a selection gene, or a gene of therapeutic interest, the AAV vector cassette being located between the two RTSs.

[0090]

[0105] In some embodiments, the disclosure provides a Chinese hamster ovary (CHO) cell comprising adenovirus (Ad) genes comprising E1A and E1B and a promoter operably linked to the Ad genes, a second Ad gene comprising E2A, E4, VA, and MIR342, adeno-associated virus (AAV) genes comprising Rep and Cap, and an AAV vector cassette comprising a reporter gene, a selection gene, a gene of therapeutic interest, or a combination thereof.

[0091]

[0106] In some embodiments, the disclosure provides a method of producing a recombinant adeno-associated virus (rAAV) producer cell comprising providing a cell comprising at least four distinct recombination target sites (RTS), an adenovirus (Ad) gene comprising E1A, E1B or a combination thereof, and a promoter operably linked to the Ad gene, wherein the RTS, the Ad genes and the promoter are integrated into a chromosome, transfecting the provided cell with a vector comprising a replaceable cassette encoding an adeno-associated virus (AAV) gene, a second Ad gene, an AAV vector cassette or a combination thereof, integrating the replaceable cassette into the chromosome, and selecting rAAV producer cells having the replaceable cassette integrated into the chromosome. In some embodiments, the transfection is with two vectors, a first vector comprising a replaceable cassette comprising the second Ad gene and the AAV gene, and a second vector comprising a replaceable cassette comprising the AAV vector cassette. In some embodiments, the transfection is with two vectors, a first vector containing a replaceable cassette containing the second Ad gene and a second vector containing a replaceable cassette containing the AAV gene. In some embodiments, the transfection is with three vectors, a first vector containing a replaceable cassette containing the second Ad gene, a second vector containing a replaceable cassette containing the AAV gene, and a third vector containing a replaceable cassette containing an AAV vector cassette. In some embodiments, each replaceable cassette further contains two RTSs that match the two RTSs of the cell. In some embodiments, the inventors have found that the use of SSIs eliminates the need for cloning from transfected cells, since the cells are homologous in their genetic makeup.

[0092]

[0107] The term "matching" with respect to two RTS sequences refers to two sequences that have the ability to bind a recombinase and affect site-specific recombination between the two sequences. In some embodiments, an RTS on a replaceable cassette that matches an RTS of a cell refers to an RTS on the cassette that has a sequence that is substantially identical to the RTS of the cell. In some embodiments, the replaceable cassette contains a sequence that is substantially identical to one or two RTSs integrated into a chromosome in the cell.

[0093]

[0108] In some embodiments, the term "integrate" refers to the integration (e.g., insertion) of an exchangeable cassette into a chromosome. In some embodiments, the integration is mediated by a site-specific recombinase.

[0094]

[0109] In some embodiments, the term "selecting" refers to identifying cells that contain a marker integrated into a chromosome. In some embodiments, selection is performed by detecting the presence of the marker using known methods. In some embodiments, selection is performed by detecting the absence of the marker using known methods.

[0095]

[0110] In some embodiments, the second Ad gene comprises E1A, E1B, E2A, E4, VA, MIR342, or a combination thereof. In some embodiments, the AAV gene is Rep, Cap, or a combination thereof. In some embodiments, the AAV vector cassette comprises a reporter gene, a selection gene, a gene of therapeutic interest, or a combination thereof.

[0096]

[0111] In some embodiments, the disclosure provides a method for producing a recombinant adeno-associated virus (rAAV), comprising: (i) infecting a host cell with rAAV; (ii) producing AAV packaged with an AAV vector cassette; and (iii) purifying the packaged rAAV, wherein the host cell comprises at least four distinct recombination target sites (RTS), an adenovirus (Ad) gene comprising E1A, E1B, or a combination thereof, and a promoter operably linked to the Ad gene, wherein the RTS, Ad gene, and promoter are integrated into a chromosome, and the host cell comprises a second Ad gene comprising E1A, E1B, E2A, E4, VA, MIR342, or a combination thereof, an adeno-associated virus (AAV) gene comprising Rep, Cap, or a combination thereof, and an AAV vector cassette comprising a reporter gene, a selection gene, a therapeutic gene, or a combination thereof. In some embodiments, a live wild-type helper virus is not required for the production and packaging of rAAV. In some embodiments, expression of E1A is not required for rAAV production. 9vg / mL of active rAAV is obtained after purification. In some embodiments of the present disclosure, rAAV is produced substantially free of replication-competent adenovirus (RCA). For example, in some embodiments of the present disclosure, RCA is below the limit of detection before purification. Methods for quantifying viral particles are known to those of skill in the art and include quantitative polymerase chain reaction (qPCR) analysis, infection titration assays, end-point dilution assays, and viral plaque assays. In some embodiments, the inventors have found that the use of SSIs in the preparation of rAAV producer cells renders the pool of producer cells homogenous in genetic makeup. In some embodiments, the inventors have found that the use of SSIs in the preparation of rAAV producer cells renders the pool of producer cells homogenous in the ratio of first helper genes to second helper genes. In some embodiments, the inventors have found that the use of SSIs in the preparation of rAAV producer cells renders the pool of producer cells homogenous in the ratio of first helper genes to second helper genes. In some embodiments, the inventors have found that the use of SSIs in preparing rAAV producer cells results in pools of producer cells that are homogenous in the ratio of helper to therapeutic genes, hi some embodiments, the inventors have found that the use of SSIs in preparing rAAV producer cells results in a more consistent quality of the rAAV product.

[0097]

[0112] As used herein, "amino acid" refers to a compound containing a carboxyl (-COOH) and an amino (-NH2) group. "Amino acid" refers to both natural and non-natural, i.e., synthetic, amino acids. Natural amino acids (along with their three letter and one letter codes) include alanine (Ala; A), arginine (Arg, R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine ​​(Cys; C), glutamine (Gln; Q), glutamic acid (Glu; E), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V).

[0098]

[0113] The terms "peptide," "polypeptide," and "protein" are used interchangeably herein to refer to polymeric forms of amino acids of any length, including coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides with modified peptide backbones.

[0099]

[0114] Desired cell lines, such as prokaryotic and / or eukaryotic cell lines, can be cultured using any suitable apparatus, facilities, and methods described herein. Furthermore, in some embodiments, the apparatus, facilities, and methods are suitable for culture of suspension cells or anchorage-dependent (attached) cells, and are suitable for manufacturing operations configured for the production of pharmaceutical and biopharmaceutical products, such as polypeptide products, nucleic acid products (e.g., DNA or RNA), or mammalian or microbial cells and / or viruses, for use in cell and / or viral and microbial therapy.

[0100]

[0115] In some embodiments, the cells express or produce a product, such as a therapeutic or diagnostic recombinant product. As described in more detail below, examples of products produced by the cells include, but are not limited to, antibody molecules (e.g., monoclonal antibodies, bispecific antibodies), antibody mimetics (polypeptide molecules that specifically bind to an antigen but are structurally unrelated to antibodies (e.g., DARPins, affibodies, adnectins, or IgNARs), fusion proteins (e.g., Fc fusion proteins, chimeric cytokines), other recombinant proteins (e.g., glycosylated proteins, enzymes, hormones), viral therapeutics (e.g., anti-cancer oncolytic viruses, viral vectors for gene therapy and viral immunotherapy), cellular therapeutics (e.g., pluripotent stem cells, mesenchymal stem cells, and adult stem cells), vaccines or lipid-encapsulated particles (e.g., exosomes, virus-like particles), RNA (e.g., siRNA), or DNA (e.g., plasmid DNA, etc.) (antibiotics) or amino acids. In embodiments, the devices, facilities, and methods may be used for the manufacture of biosimilars.

[0101]

[0116] As described above, in embodiments, the apparatus, facilities, and methods allow for large-scale production of eukaryotic or prokaryotic products (e.g., proteins, peptides, antibiotics, amino acids, nucleic acids (e.g., DNA or RNA) synthesized by eukaryotic cells (e.g., mammalian cells) or lower eukaryotic cells (e.g., yeast cells or filamentous fungal cells), or prokaryotic cells (e.g., gram-positive or gram-negative cells), and / or eukaryotic cells. In some embodiments, the use of microorganisms and their spores for microbiota therapy is also disclosed. Unless otherwise specified herein, the apparatus, facilities, and methods may include any desired volume or production capacity, including, but not limited to, bench scale, pilot scale, and full production scale.

[0102]

[0117] Further, unless otherwise stated herein, the apparatus, facilities and methods may comprise any suitable reactor, including, but not limited to, stirred tank, airlift, fiber, microfiber, hollow fiber, ceramic matrix, fluidized bed, fixed bed and / or spouted bed bioreactors. As used herein, a "reactor" may comprise a culture tank or a cultivation unit, or any other reaction vessel, and the term "reactor" is used interchangeably with "culture tank." The term "culture tank" or "cultivation" refers to the cultivation of both microorganisms and mammalian tissues. For example, in some embodiments, an exemplary bioreactor unit may perform one or more or all of the following: feeding nutrients and / or carbon sources, injecting appropriate gases (e.g., oxygen), pumping and evacuating fermentation or cell culture media, separating gas and liquid phases, maintaining temperature, maintaining oxygen and CO2 levels, maintaining pH levels, agitating (e.g., rotating), and / or cleaning / sanitizing. An exemplary reactor unit (e.g., a culture unit) may include multiple reactors within the unit, e.g., the unit may have 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, or 100 or more unit bioreactors, and / or the facility may have multiple units with single or multiple reactors within the facility. In various embodiments, the bioreactor may be suitable for batch, semi-fed-batch, fed-batch, perfusion, and / or continuous fermentation processes. The diameter of the reactor may be adjusted accordingly. In embodiments, the bioreactor may have a volume of about 100 mL to about 50,000 L.Non-limiting examples include 100mL, 250mL, 500mL, 750mL, 1L, 2L, 3L, 4L, 5L, 6L, 7L, 8L, 9L, 10L, 15L, 20L, 25L, 3 0L, 40L, 50L, 60L, 70L, 80L, 90L, 100L, 150L, ​​200L, 250L, 300L, 350L, 400L, 450L, 500L, 550L, 600 Included are volumes of 1000 L, 650 L, 700 L, 750 L, 800 L, 850 L, 900 L, 950 L, 1000 L, 1500 L, 2000 L, 2500 L, 3000 L, 3500 L, 4000 L, 4500 L, 5000 L, 6000 L, 7000 L, 8000 L, 9000 L, 10,000 L, 15,000 L, 20,000 L, and / or 50,000 L. Furthermore, suitable reactors may be multi-use, single-use, disposable, or non-disposable and may be formed from any suitable material, such as metal alloys (e.g., stainless steel (e.g., 316L or any other suitable stainless steel) and Inconel), plastic, and / or glass.

[0103]

[0118] In embodiments, unless otherwise stated herein, the apparatus, facilities, and methods described herein may comprise any other suitable operational units and / or equipment not described, such as operational units and / or equipment for separation, purification, and isolation of such products. Any suitable facility and environment may be used, such as conventional field assembled facilities, modular, mobile and temporary facilities, or any other suitable construction, facility, and / or layout. For example, in some embodiments, modular clean rooms may be used. Furthermore, unless otherwise stated herein, the apparatus, systems, and methods described herein may be stored and / or performed in a single location or facility, or may be stored and / or performed in separate or multiple locations and / or facilities.

[0104]

[0119] Non-limiting examples of facilities, equipment and / or systems that may be suitable include, but are not limited to, those described in U.S. Patent Application Publication Nos. 2013 / 0280797, 2012 / 0077429, 2011 / 0280797, 2009 / 0305626, and U.S. Patent Nos. 8,298,054, 7,629,167, and 5,656,491, the entire disclosures of which are incorporated herein by reference.

[0105]

[0120] In an embodiment, the cell is a eukaryotic cell (e.g., a mammalian cell). For example, the mammalian cell can be a human or rodent or bovine cell line or cell strain. For example, examples of such cells, cell lines or cell strains include mouse myeloma (NSO) cell lines, Chinese hamster ovary (CHO) cell lines, HT1080, H9, HepG2, MCF7, MDBK Jurkat, NIH3T3, PC12, BHK (baby hamster kidney cells), VERO, SP2 / 0, YB2 / 0, Y0, C127, L cells, COS (e.g., COS1 and COS7), QC1-3, HEK293, VERO, PER.C6, HeLa, EBl, EB2, EB3, oncolytic or hybridoma cell lines. Preferably, the mammalian cell is a CHO cell. In one embodiment, the cell is a CHO cell. In one embodiment the cell is a CHO-K1 cell, a CHOK1SV™ cell, a DG44 CHO cell, a DUXB11 CHO cell, a CHOS, a CHO GS knockout cell, a CHO FUT8 GS knockout cell, a CHOZN or a CHO derived cell. A CHO GS knockout cell (e.g. a GSKO cell) is for example a CHOK1SV GS-KO (part of Lonza's Xceed® Expression system (Lonza, Slough, UK)). A CHO FUT8 knockout cell is for example a CHOK1SV™ Potelligent® (Lonza, Slough, UK). The eukaryotic cell may be an avian cell, cell line or cell line (e.g. an EBx® cell, EB14, EB24, EB26, EB66 or EBvl3).

[0106]

[0121] In some embodiments, the eukaryotic cells are stem cells. The stem cells may be, for example, pluripotent stem cells, including embryonic stem cells (ESCs), adult stem cells, induced pluripotent stem cells (iPSCs), tissue-specific stem cells (e.g., hematopoietic stem cells), and mesenchymal stem cells (MSCs).

[0107]

[0122] In one embodiment, the cells are any differentiated form of the cells described herein. In one embodiment, the cells are derived from any primary cell in culture. In some embodiments, the cells are not derived from stem cells. For example, in some embodiments, the cells are used in immunotherapy as cells (e.g., lymphocytes) extracted and isolated from an individual patient or obtained from an established cell bank. In some embodiments, the cells may include genetically engineered cells (i.e., CAR-T, etc.).

[0108]

[0123] In embodiments, the cells are hepatocytes (e.g., human hepatocytes, animal hepatocytes, or non-parenchymal cells). For example, the cells may be plateable human hepatocytes for metabolism studies, plateable human hepatocytes for induction studies, plateable Qualyst Transporter Certified™ human hepatocytes, human hepatocytes for suspension culture (including 10 donor and 20 donor pooled hepatocytes), human hepatic Kupffer cells, human hepatic stellate cells, dog hepatocytes (including single and pooled beagle hepatocytes), mouse hepatocytes (including CD-1 and C57BI / 6 hepatocytes), rat hepatocytes (including Sprague-Dawley, Wistar Ham, and Wistar hepatocytes), monkey hepatocytes (including Cynomolgus or Rhesus hepatocytes), cat hepatocytes (including domestic and short-haired cat hepatocytes), and rabbit hepatocytes (including New Zealand White hepatocytes). Hepatocytes are commercially available, for example, from Triangle Research Labs, LLC (6 Davis Drive, Research Triangle Park, North Carolina, USA 27709).

[0109]

[0124] In one embodiment, the eukaryotic cell is a lower eukaryotic cell, such as a yeast cell (e.g., a member of the genus Pichia (e.g., Pichia pastoris, Pichia methanolica, Pichia kluyveri, and Pichia angusta), a member of the genus Komagataella (e.g., Komagataella pastoris, Komagataella pseudopastoris, or Komagataella phaffii), a member of the genus Saccharomyces (e.g., Saccharomyces cerevisiae, Saccharomyces kluyveri, Saccharomyces uvarum ... uvarum), Kluyveromyces (e.g. Kluyveromyces lactis, Kluyveromyces marxianus), Candida (e.g. Candida utilis, Candida cacaoi, Candida boidinii), Geotrichum (e.g. Geotrichum fermentans), Hansenula polymorpha, Yarrowia lipolytica or Schizosaccharomyces pombe). Pichia pastoris species are preferred. Examples of Pichia pastoris strains are X33, GS115, KM71, KM71H and CBS7435.

[0110]

[0125] In one embodiment, the eukaryotic cell is a fungal cell, such as a fungal cell, such as an Aspergillus (e.g., A. niger, Aspergillus fumigatus, A. orzyae, A. nidula), Acremonium (e.g., A. thermophilum), Chaetomonium (e.g., C. thermophilum), Chrysosporium (e.g., C. thermophilum), Cordyceps (e.g., C. militaris), Corynascus, Ctenomyces, Fusarium (e.g., F. oxysporum), Glomerella (e.g., G. graminicola), Hypocrea (e.g., H. jejuni), or a fungal cell, such as ... h. corina (H. jecorina), Magnaporthe (e.g. M. orzyae), Myceliophthora (e.g. M. thermophile), Nectria (e.g. N. heamatococca), Neurospora (e.g. N. crassa), Penicillium, Sporotrichum (e.g. S. thermophile), Thielavia (e.g. T. terrestris, T. heterothallica), Trichoderma (e.g. T. reesei) or Verticillium (e.g. V. dahlia).

[0111]

[0126] In one embodiment, the eukaryotic cell is an insect cell (e.g., an Sf9, Mimic™ Sf9, Sf21, High Five™ (BT1-TN-5B1-4) or BT1-Ea88 cell), an algae cell (e.g., an Amphora, a diatom, Dunaliella, Chlorella, Chlamydomonas, Cyanophyta (cyanobacteria), Nannochloropsis, Spirulina or Ochromonas), or a plant cell (e.g., a cell from a monocotyledonous plant (e.g., corn, rice, wheat or green foxtail), or a cell from a dicotyledonous plant (e.g., cassava, potato, soybean, tomato, tobacco, alfalfa, Physcomitrella patens or Arabidopsis).

[0112]

[0127] In one embodiment, the cell is a bacteria or a prokaryotic cell. In some embodiments, the prokaryotic cell is a gram-positive cell (e.g., Bacillus, Streptomyces, Streptococcus, Staphylococcus, or Lactobacillus). Bacillus can be used, for example, B. subtilis, B. amyloliquefaciens, B. licheniformis, B. natto, or B. megaterium. In an embodiment, the cell is B. subtilis (e.g., B. subtilis 3NA and B. subtilus 168). For example, Bacillus can be obtained from the Bacillus Genetic Stock Center (Biological Sciences 556, 484 West 12th Avenue, Columbus OH 43210-1214).

[0113]

[0128] In one embodiment, the prokaryotic cells are gram-negative cells, such as Salmonella spp. or E. coli (e.g., TG1, TG2, W3110, DH1, DHB4, DH5a, HMS 174, HMS174(DE3), NM533, C600, HB101, JM109, MC4100, XL1-Blue, and Origami), as well as cells derived from E. coli B-strains (e.g., BL-21 or BL21(DE3)), all of which are commercially available. Suitable host cells are commercially available, for example, from microorganism collections such as the DSMZ (Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH, Braunschweig, Germany) or the American Type Culture Collection (ATCC). In some embodiments, the cells include other microorganisms utilized as therapeutic agents. These include the microbiota present in the human microbiome belonging to Firmicutes, Bacteroidetes, Proteobacteria, Verrumicrobia, Actinobacteria, Fusobacteria and Cyanobacteria. The microbiota can be aerobic, obligately anaerobic or facultatively anaerobic, and can include cells or spores. Therapeutic microbiota also include genetically engineered organisms and the vectors used in their engineering. Other microbiome-related therapeutic organisms include archae, fungi and viruses. See, for example, The Human Microbiome Project Consortium. Nature 486, 207-214 (14 June 2012); Weinstock, Nature, 489(7415): 250-256(2012); Lloyd-Price, Genome Medicine 8:51(2016).

[0114]

[0129] In some embodiments, the cultured cells are used to produce proteins for therapeutic use, such as antibodies (e.g., monoclonal antibodies) and / or recombinant proteins. In embodiments, the cultured cells produce peptides, amino acids, fatty acids, or other useful biochemical intermediates or metabolites. For example, in embodiments, molecules having molecular weights from about 4000 Daltons to greater than about 140,000 Daltons can be produced. In embodiments, these molecules can have a range of complexity and can include post-translational modifications such as glycosylation.

[0115]

[0130] In embodiments, the protein is, for example, Botox, Myoblock, Neuroblock, Dysport (or other serotypes of botulinum neurotoxin), alglucosidase alfa, daptomycin, YH-16, choriogonadotropin alfa, filgrastim, cetrolexil, interleukin-2, aldesleukin, cteceleulin, denileukin difitox, interferon alfa-n3 (injection). , interferon alpha-nl, DL-8234, interferon, Suntory (gamma-1a), interferon gamma, thymosin alpha 1, tasonermin, DigiFab, biperatab, etitab, CroFab, nesiritide, abatacept, alefacept, rebif, eptotermin alpha, teriparatide (osteoporosis), calcitonin injectable (bone disease), calcitonin (nose, osteoporosis), etanercept, hemoglobin glutamate 250 (bovine), Drotrecogin alpha, Collagenase, Carperitide, recombinant human epidermal growth factor (topical gel, wound healing), DWP401, Darbepoetin alpha, Epoetin omega, Epoetin beta, Epoetin alpha, Desirudin, Lepirudin, Bivalirudin, Nonacog alpha, Mononine, Eptacog alpha (activated), recombinant factor VIII + VWF, Recombinant, recombinant factor VIII, Factor VIII (recombinant), Alphnmate, Octocog alpha, Factor VIII, Palifermin, Indikinase, Tenecteplase, Alteplase, Pamiteplase, Reteplase, Nateplase, Monteplase, Follicle-stimulating hormone alpha, rFSH, hpFSH, Mi Kafungin, pegfilgrastim, lenograstim, nartograstim, sermorelin, glucagon, exenatide, pramlintide, iniglucerase, galsulfase, leucotropin, molgramostim, triptorelin acetate, hysterelin (subcutaneous implant, Hydron), deslorelin, hysterelin, nafarelin, leuprolide sustained release depot (ATRIGEL), leuprolide implant (DUROS), goserelin, Eutropin, KP-102 program, somatropin, mecasermin (growth failure), enlfavirtide, Org-33408, insulin glargine,Insulin glulisine, insulin (inhaled), insulin lispro, insulin detemir, insulin (buccal, RapidMist), mecasermin linfavert, anakinra, cermoleukin, 99mTc-apsitide injection, myelopid, betaseron, glatiramer acetate, Gepon, sargramostim, oprelvekin, human leukocyte-derived alpha interferon, Bilive, insulin (recombinant), Recombinant human insulin, insulin aspart, mecasenin, Roferon-A, interferon-α2, alphaferon, interferon alfacon-1, interferon α, Avonex recombinant human luteinizing hormone, dornase α, trafermin, ziconotide, taltirelin, divotermin α, atosiban, becaplermin, eptifibatide, Zemaila, CTC-111, Shanvac-B, HPV vaccine (quadrivalent ), octreotide, lanreotide, ancestim, agalsidase beta, agalsidase alpha, laronidase, copper acetate prezatide (topical gel), rasburicase, ranibizumab, Actimmune, PEG-Intron, Trichomin, recombinant mite allergy desensitizing injection, recombinant human parathyroid hormone (parathyroid hormone) 1-84 (sc, osteoporosis), epoetin delta, transgenic antithrombin III, grand-tro Granditropin, Vitrase, recombinant insulin, interferon-alpha (oral lozenge), GEM-21S, vapreotide, idursulfase, omapatrilat, recombinant serum albumin, certolizumab pegol, glucarpidase, human recombinant C1 esterase inhibitor (angioedema), lanoteplase, recombinant human growth hormone, enfuvirtide (needle-free injection, Biojector 2000), VGV-1, interferon-alpha, lucinactant, aviptadil (inhalation, pulmonary disease), icatibant, ecallantide, omiganan, aurograb, pexiganan acetate, ADI-PEG-20, LDI-200, degarelix,cintredelin besudotox, Favld, MDX-1379, ISAtx-247, liraglutide, teriparatide (osteoporosis), tifacogin, AA4500, T4N5 liposomal lotion, catumaxomab, DWP413, ART-123, Chrysalin, desmoteplase, amediplase, corifollitropin alfa, TH-9507, teduglutide, Diamyd, DWP-412, growth hormone (sustained release infusion), recombinant G-CSF, insulin (inhaled, AIR) , insulin (inhaled, Technosphere), insulin (inhaled, AERx), RGN-303, DiaPep277, interferon beta (hepatitis C virus infection (HCV)), interferon alpha-n3 (oral), belatacept, transdermal insulin patch, AMG-531, MBP-8298, Xerecept, Opevacan, AIDSVAX, GV-1001, LymphoScan, ranpirnase, Lipoxysan, Rusplutide, MP52 (β -tricalcium phosphate carrier, bone regeneration), melanoma vaccine, sipuleucel-T, CTP-37, Insegia, vitespen, human thrombin (freezing, surgical bleeding), thrombin, TransMID, alfimeprase, Puricase, terlipressin (intravenous, hepatorenal syndrome), EUR-1008M, recombinant FGF-I (injectable, vascular disease), BDM-E, rotigaptide, ETC-216, P-113, MBI-594AN, duramycin (inhalation, cystic fibrosis), SC V-07, OPI-45, endostatin, angiostatin, ABT-510, Bowman-Birk inhibitor concentrate, XMP-629, 99mTc-hynic-annexin V, kahalalide F, CTCE-9908, teverelix (extended release), ozarelix, romidepsin, BAY-504798, interleukin 4, PRX-321, Pepscan, ivoctadekin, rh lactoferrin, TRU-015,IL-21, ATN-161, cilengitide, Albuferon, Biphasix, IRX-2, omega interferon, PCK-3145, CAP-232, pasireotide, huN901-DMI, ovarian cancer immunotherapy vaccine, SB-249553, Oncovax-CL, Oncovax-P, BLP-25, CerVax-16, multi-epitope peptide melanoma vaccine (MART-1, gp100, tyrosinase), nemifitide, rAAT (inhaled), rAAT (dermatological), CGRP (inhaled, asthma), pegsnercept, thyroid cancer Mosin β4, plitidepsin, GTP-200, ramoplanin, GRASPA, OBI-1, AC-100, salmon calcitonin (oral, eligen), calcitonin (oral, osteoporosis), examorelin, capromorelin, Cardeva, bellafermin, 131I-TM-601, KK-220, T-10, ularitide, deperestat, hematide, Chrysalin (topical), rNAPc2, recombinant factor V111 (PEGylated liposome), bFGF, PEGylated recombinant staphylokinase variant, V-10153, sonolysis Prolease, NeuroVax, CZEN-002, islet cell neogenesis treatment, rGLP-1, BIM-51077, LY-548806, exenatide (controlled release, Medisorb), AVE-0010, GA-GCB, avorelin, ACM-9604, linaclotid eacetate, CETi-1, Hemospan, VAL (injectable), fast acting insulin (injectable, Viadel), intranasal insulin, insulin (inhaled), insulin (oral, eligen), recombinant methionyl human leptin, pitrakinra (subcutaneous injection, eczema), pitrakinra (dry powder for inhalation, asthma), Multikine, RG-1068, MM-093, NBI-6024, AT-001, PI-0824, Org-39141, Cpn10 (autoimmune disease / inflammation), talactoferrin (topical), rEV-131 (eye), rEV-131 (respiratory disease), oral recombinant human insulin (diabetes), RPI-78M,Oprelvekin (oral), CYT-99007 CTLA4-Ig, DTY-001, Balategrast, Interferon alfa-n3 (topical), IRX-3, RDP-58, Tauferon, Bile salt stimulated lipase, Melispase, Alkaline phosphatase, EP-2104R, Melanotan-II, Brimelanotide, ATL-104, Recombinant human microplasmin, AX-200, SEMAX, ACV-1, Xen-2174, CJC-1008, Dynorphin A, SI-6603, LAB GHRH, AER-002, BGC-728, Malaria vaccine (virosomes, PeviPRO), ALTU-135, Parvovirus B19 vaccine, Influenza vaccine (recombinant neuraminidase), Malaria / HBV vaccine, Anthrax vaccine, Vacc-5q, Vacc-4x, HIV vaccine (oral), HPV vaccine, Tat toxoid, YSPSL, CHS-13340, PTH(1-34) liposome cream (Novasome vasome), Ostabolin-C, PTH analogues (topical, psoriasis), MBRI-93.02, MTB72F vaccine (tuberculosis), MVA-Ag85A vaccine (tuberculosis), FARA04, BA-210, recombinant plague FIV vaccine, AG-702, OxSODrol, rBetV1, Der-p1 / Der-p2 / Der-p7 allergen targeting vaccine (mite allergy), PR1 peptide antigen (leukemia), mutant ras vaccine, HPV-16 E7 lipopeptide vaccine, labyrinthin vaccine (adenocarcinoma), CML vaccine, WT1-peptide vaccine (cancer), IDD-5, CDX-110, Pentrys, Norelin, CytoFab, P-9808, VT-111, Icrocaptide, Telbermin (skin disease, diabetic foot ulcer), Rupintrivir, reticulose, rGRF, HA, alpha-galactosidase A, ACE-011, ALTU-140, CGX-1160, angiotensin therapeutic vaccine, D-4F, ETC-642, APP-018, rhMBL, SCV-07 (oral drug, tuberculosis), DRF-7295, ABT-828, ErbB2-specific immunotoxin (anticancer), DT3SSIL-3, TST-10088,PRO-1762, Combotox, cholecystokinin-B / gastrin receptor binding peptide, 111In-hEGF, AE-37, trasnizumab-DM1, antagonist G, IL-12 (recombinant), PM-02734, IMP-321, rhIGF-BP3, BLX-883, CUV-1647 (, topical), L-19-based radioimmunotherapeutic (cancer), Re-188 P-2045, AMG-386, DC / 1540 / KLH vaccine (cancer), VX-001, AVE-9633, AC-9301, NY-ESO-1 vaccine (peptide), NA17.A2 peptide, melanoma vaccine (therapeutic pulsed antigen), prostate cancer vaccine, CBP-501, recombinant human lactoferrin (dry eye), FX-06, AP-214, WAP-8294A (injectable), ACP-HIP, SUN-11031, peptide YY[3-36] (obesity, nasal), FGLL, atacicept, BR 3-Fc, BN-003, BA-058, human parathyroid hormone 1-34 (nose, osteoporosis), F-18-CCR1, AT-1100 (celiac disease / diabetes), JPD-003, PTH(7-34) liposomal cream (Novasome), duramycin (eye, dry eye), CAB-2, CTCE-0214, glycoPEGylated erythropoietin, EPO-Fc, CNTO-528, AMG-114, JR-013, factor XIII, aminocandin, PN-951, 716155, SUN-E7001 , TH-0318, BAY-73-7977, teverelix (immediate release), EP-51216, hGH (controlled release, Biosphere), OGP-I, sifuvirtide, TV4710, ALG-889, Org-41259, rhCC10, F-991, thymopentin (lung disease), r(m)CRP, liver selective insulin, subalin, L19-IL-2 fusion protein, elafin, NMK-150, ALTU-139, EN-122004, rhTPO, thrombopoietin receptor agonist (thrombocytopenic disorders), AL-108, AL-208, nerve growth factor antagonists (pain), SLV-317, CGX-1007, INNO-105, oral teriparatide (Erigen), GEM-OS1, AC-162352, PRX-302, LFn-p24 fusion vaccine (Therapore), EP-1043, pediatric S pneumonia vaccine, malaria vaccine, meningococcal group B vaccine, neonatal group B streptococcal vaccine, anthrax vaccine, HCV vaccine (gpE1+gpE2+MF-59), otitis media treatment,HCV vaccine (core antigen + ISCOMATRIX), hPTH(1-34) (transdermal, ViaDerm), 768974, SYN-101, PGN-0052, Aviscumin, BIM-23190, tuberculosis vaccine, multi-epitope tyrosinase peptide, cancer vaccine, enkastim, APC-8024, GI-5005, ACC-001, TTS-CD3, vascular targeted TNF (solid tumors) (desmopressin) (buccal, sustained release), onercept and TP-9201.

[0116]

[0131] In some embodiments, the polypeptide is adalimumab (HUMIRA), infliximab (REMICADE™), rituximab (RITUXAN™ / MABTHERA™), etanercept (ENBREL™), bevacizumab (AVASTIN™), trastuzumab (HERCEPTIN™), pegrillgrastim (NEULASTA™), or any other suitable polypeptide, including biosimilars and biobetters.

[0117]

[0132] Other suitable polypeptides are those set forth in Table 6 below and in Table 1 of U.S. Patent Application Publication No. 2016 / 0097074. One of skill in the art will recognize that the present disclosure further encompasses combinations of the products and / or conjugates described herein (i.e., multi-proteins, modified proteins (conjugates to PEG, toxins, other active ingredients).

[0118] [Table 6] TIFF0007637470000008.tif210149 TIFF0007637470000009.tif210149 TIFF0007637470000010.tif85149

[0119]

[0133] In some embodiments, the polypeptide is a hormone, blood clotting / clotting factor, cytokine / growth factor, antibody molecule, fusion protein, protein vaccine, or peptide shown in Table 7.

[0120] [Table 7] TIFF0007637470000012.tif215149

[0121]

[0134] In some embodiments, the protein is a multispecific protein (eg, a bispecific antibody as shown in Table 8).

[0122] [Table 8] TIFF0007637470000014.tif164149 TIFF0007637470000015.tif171149 TIFF0007637470000016.tif157149 TIFF0007637470000017.tif179149 TIFF0007637470000018.tif113149

[0123]

[0135] To realize the benefits of the system for therapeutic proteins, the CHOK1SV SSI containing multiple RTS sites can be tested for expression of therapeutic proteins as outlined in Table 10. The experiment can be divided into three phases; Phase 1: Testing the use of multi-site SSI to increase qP; Phase 2: Testing the ability of multi-site SSI to express a three-gene bispecific mAb across two SSISs; Phase 3: Expressing ancillary genes at one site to support expression of the DtE protein encoded at the other site.

[0124]

[0136] Phase 1: A limitation of some cell lines containing a single RTS site is that a single copy of the required transcription unit is not sufficient to generate adequate titers for clinical manufacturing. Therefore, we can evaluate the option of using multiple RTSs and increasing the integrated copy number of the mAb gene. In such a method, the mAb gene can be targeted to landing pads A and B. The homogeneity of the pool can be determined by FACS sorting and analysis of the supernatant by Protein A HPLC.

[0125]

[0137] Phase 2: For the majority of next generation antibodies (e.g. tetravalent bispecific antibodies), the assembly of multiple heavy or light chains is a recurring challenge. To obtain optimal product quality with minimal unwanted by-products, it is useful to select suitable CHO clones that stably and reproducibly express the four antibody chains. As a result, during clone selection, analysis of many products using ELISA, RP-HPLC or CD-SDS is often required. However, in cell lines containing multiple RTSs, the genes encoding the multi-chain proteins are spatially separated into two sites with individual promoters. This ensures that the copy number and relative expression of the individual chains are early aligned with the transfectant pool, allowing effective empirical fine-tuning of the obtainability of the individual polypeptide chains by manipulating the promoter strength or copy number of the encoding transcription unit. The advantages include a more uniform product quality, a reduced proportion of misfolded multi-chain recombinant proteins produced from SSI generation pools and cell lines, and a dramatic reduction in the need for early stage evaluation. Test molecule: cergutumab amunaleukin.

[0126]

[0138] Phase 3: Expression of endogenous proteins resulting in increased secretion capacity of the CHOK1SV GS-KO™ cell line is an established method to increase product titer. Candidates can be identified from WO 2015 / 018703A1 and those in Tables 9 and 10 can be evaluated against cell lines containing multiple distinct recombination target sites (RTS). Product titers can be measured by Protein A HPLC and antibody aggregates can be evaluated by SDS-PAGE and IEF. Test molecules: Rituximab, cB72.3, Infliximab and Etanercept.

[0127] [Table 9]

[0128] [Table 10] EXAMPLES

[0129] Example 1: Transient AAV production of CHOK1SV GS-KO™ by co-infection with Adenovirus 5 virus

[0139] To determine whether CHOK1SV GS-KO™ (Lonza, Slough, UK) cells were biologically capable of producing and assembling rAAV vector proteins, CHOK1SV GS-KO™ cells were transfected with two plasmids, pRC2-mi342 (6234, Clontech) and pAAV-GFP (AAV-400, Cell Biolabs) control vector (Cat. No. AAV-400 Cell Biolabs, San Diego, USA) ( FIG. 6 ), in the presence of wild-type Ad5 virus (Cat. No. ATCC® VR-1516™, ATCC, Manassas, USA). In native conditions, CHOK1SV GS-KO™ cells do not receive adenovirus because they lack a viral receptor, but in the presence of cationic transfection reagents (lipofectamine or PEI), the negatively charged adenovirus 5 is able to enter CHOK1SV GS-KO™ cells, providing all helper elements. This concept was used in designing the present evaluation experiments, in which CHOK1SV GS-KO™ cells are provided with all elements (Rep-Cap and GOI by transfection, and Ad5 elements by infection). Cells were harvested 72 hours after transfection / infection and lysed by four freeze / thaw cycles, followed by benzonase treatment to digest any plasmid DNA. Lysates were used to test AAV titers by qPCR and transgene (green fluorescent protein: GFP) expression by transduction efficiency into HEK293. As a control for this experiment, adherent HEK293 cells were used and cell lysates from triple-transfected (pHelper (6234, Clontech), pRC2-mi342 (6234, Clontech), pAAV-GFP (AAV-400, Cell Biolabs) (Figure 6)) HEK293 cells were analyzed as well as CHOK1SV GS-KO™ cells transfected with pRC2-mi342 (6234, Clontech) (pAAV-GFP) and infected with wild-type Ad5.The outline of the experiment and the results of this experiment are shown in Figure 1. After transfection, green fluorescence was detected in CHOK1SV GS-KO™ cells, indicating successful transfection (Figure 1B, left panel). The lysate of transfected CHOK1SV GS-KO™ cells was used to transduce HEK293 cells, but only low green fluorescence was detected in HEK293 cells (Figure 1B, right panel), suggesting low-level production of AAV. qPCR data shows an AAV titer of 6.8E+09 vg / mL (Figure 1C). As expected, the positive control, triple-transfected HEK293, produced a high AAV titer of 1.8e+12, while no AAV was produced in the negative control (HEK293 GFP transfection). In summary, this is the first experiment to demonstrate that CHOK1SV GS-KO™ cells are capable of producing AAV when provided with all known genomic elements required for AAV packaging.

[0130] Example 2: Transient rAAV production of CHOK1SV GS-KO™ without viral co-infection

[0140] To determine whether CHOK1SV GS-KO™ cells could produce rAAV in the absence of wild-type Ad5 virus, cells expressing Ad5 E1A and E1B were generated by an approach similar to Howe et al., 2005. Plasmid constructs were constructed expressing E1A under the control of the TET-on promoter (pMF30, FIG. 2) and E1B under the control of the constitutive human CMV promoter (pMF23, FIG. 3) and the Ad5 E1A-E1B open reading frame (pXC17.4_17AV5PerProKZ, FIG. 4). CHOK1SV GS-KO™-derived pools were constructed by transfecting pMF30 and selecting for cells viable in glutamine-free medium supplemented with 50 μM L-MSX (FIG. 5A). This CHOK1SV GS-KO™ E1A was then transfected with pMF23 and cells viable in glutamine-free medium supplemented with 50 μM L-MSX and 10 μg / mL puromycin were selected (FIG. 5A). Although water controls were included in all genomic DNA PCRs, it is clear that E1A PCR products were amplified in HEK293F and HEK293L cells and pXC17.4_17AV5PerProKZ (FIG. 1B). CHOK1SV GS-KO™ MOCK (MOCK) and CHOK1SV GS-KO™ E1A E1B (E1A E1B) pools were treated with doxycycline (2 μg / ml) for 0 (untreated), 2, 3, 4 and 7 days to activate the TET promoter and E1A transcription, and then mRNA was isolated for reverse transcription PCR using primers for E1A (FIG. 1D) and E1B (FIG. 1E). The results showed that the levels of E1A 243R and E1A 171R were high in CHOK1SV GS-KO™ E1A E1B pools and HEK293L cells treated with doxycycline. The amount of E1B mRNA product was unchanged after doxycycline treatment, but was significantly higher in HEK293L cells.E1A protein was detected in the CHOK1SV GS-KO™ E1A E1B pool treated with doxycycline for 7 days (E1A E1B), but not in the CHOK1SV GS-KO™ MOCK (MOCK) protein lysate (Figure 5F). This CHOK1SV GS-KO™ E1A_E1B pool was then used to test the production capacity of rAAV in the presence or absence of doxycycline (2 μg / ml). To ensure high expression of E1A and E1B proteins, we also transiently transfected CHOK1SV GS-KO™ cells with the E1A-E1B plasmid (pXC17.4_17AV5PerProKZ, Figure 4). These data indicate that E1A protein expression can be achieved in CHO without the need for wild-type Ad infection. E1B integration and expression was more difficult to confirm.

[0131] Example 3: Persistent rAAV production in CHOK1SV GS-KO™ and HEK293 without viral co-infection

[0141] As loci identified from recombinant CHOK1SV™ cell lines, landing pads suitable for subsequent RMCE were integrated into the CHOK1SV GS-KO™ and HEK293 genomes (Fer1L4, NL1, 2, 3, 4, 5 and 6, see WO 2013 / 190032 A1 and EP 2711428 A1). A schematic of the arrangement of elements within these landing pads is shown in Figures 7A, B and C. The placement of Frt sites between the SV40E promoter and the selection marker allows for its use in the next round of RMCE. The use of incompatible Frt sites (A, B, C, D, E and F) and different reporter / selection markers ensures independent identification of these sites. FIG. 8 shows various configurations of AAV, Ad5 and GOI genes in CHO and HEK293 derived SSI cell lines after RMCE, with configurations 1 (FIG. 8A), 2 (FIG. 8B) and 3 (FIG. 8C).

[0132]

[0142] To generate the HEK293 SSI host, the CHOK1SV-derived vector integration site and landing pad location were BLAT searched against the human genome using a standalone copy of the University of California Santa Cruz (UCSC) human genome database (version: March 2006 (NCBI36 / hg18)). Sequence similarity of 95% (or more) was identified over at least 25 base pairs of CHOK1SV sequence. Regions of similarity were visualized with the IGV viewer (Broad institute version 2.4). Crispr-Cas9 gRNAs were designed using an in-house Crispr-Cas9 design tool. The loci of CHOK1SV and HEK293 are summarized in Table A.

[0133] Example 4: Supplementary gene expression enhances rAAV production in CHOK1SV GS-KO™

[0143] The mammalian innate immune system senses viral infection by recognizing the viral signature and activates an antiviral response (e.g., RIG-1 IFNα response). There is a lot of evidence that RNA silencing or RNA interference (RNAi) is useful as an antiviral mechanism in mammalian cells. Mammalian viruses encode IFN antagonists (e.g., influenza NS1 protein and vaccinia virus E3L protein) (see, e.g., de Vries et al, Gene Ther., 15:545-52 (2008)), which inhibit PKR, and soluble IFN-α / β receptor decoys encoded by vaccinia virus counteract the IFN response of infected cells. Co-expression of IFN antagonists can be considered as a possible approach to overcome the low Ad5 and AAV gene expression observed in Examples 2 and 3.

[0134] Example 5: rAAV production in CHOK1SV GS-KO™ using site-specific integration Section 1: Construction of the dual landing pad CHOK1SV GS-KO™ SSI host

[0144] The CHOK1SV GS-KO™ SSI host was generated by inserting two landing pads into the genome of the CHOK1SV GS-KO™ host (FIG. 9). Landing pad A is located at the Fer1L4 gene (see Table 10) and consists of the SV40 early promoter (SV40E), the hygromycin phosphotransferase-eGFP fusion gene (Hpt-eGFP), and the SV40 polyadenylation sequence (pA). The Hpt-eGFP gene and the SV40 pA are flanked by incompatible Frt sites (Frt_5 and Frt_wt, respectively) to facilitate RMCE of the recombinant gene into the CHOK1SV GS-KO™ genome. Landing pad B is located at the NL1 locus (see Table A) and consists of the SV40 early promoter (SV40E), the puromycin N-acetyltransferase-DsRed fusion gene (PAC-DsRed), and the SV40 polyadenylation sequence (pA). The PAC-DsRed gene and SV40 pA are flanked by incompatible Frt sites (Frt14 and Frt15, respectively). In both landing pads, the placement of an Frt site between the SV40E promoter and the selection marker allows for its use in the next round of RMCE. The targeting vector designed for RMCE in the CHOK1SV GS-KO™ SSI host contains a positive selection marker (e.g., GS) placed immediately 3' of an Frt site compatible with the landing pad of interest (Figure 9). The remainder of the vector contains the transcription unit for the GOI followed by an Frt site compatible with the second Frt site in the landing pad. The targeting vector DNA (Figure 10) is co-transfected with a vector expressing Flp recombinase. The transfected cells are incubated for 24 hours and then selection pressure is applied (e.g., removal of glutamine from the medium). Successful RMCE is indicated by loss of the Hpt-eGFP or PAC-DsRed gene and replacement with the positive selection marker gene. The cells appear dark under a fluorescent microscope or by flow cytometer analysis. Non-exchanged cells that have reverted upon positive selection are easily removed by FACS.

[0135] Section 2: Construction of Rep-Cap and GOI expression vectors compatible with CHOK1SV GS-KO™ SSI host

[0145] To generate pools from CHOK1SV GS-KO™ SSI hosts expressing Rep-Cap and GOI genes (Figure 9), five vectors were designed (pLMC31-35, Figures 10A-E). pLMC31 (Figure 10A) is a targeting vector for generating GOI (eGFP) producing cell lines of CHOK1SV GS-KO™ SSI hosts. Transcription of eGFP is driven by the promoter of the hCMV major intermediate early gene 1 (hCMV) and uses the β-globin polyadenylation (pA) sequence. All transcription cassettes are flanked by inverted terminal repeats (ITRs), the only cis-acting elements required for viral replication and packaging. The neomycin phosphotransferase I (nptI) gene is located immediately 3' to Frt14, and transcription of RMCE is well activated by the SV40E promoter located in the landing pad of the NL1 locus. pLMC32-35 (Fig. 10B-E) are targeting vectors with different conformations of the AAV p5 promoter and Rep-Cap expression cassettes to generate CHOK1SV GS-KO™ SSI host (Fig. 10B-E) cell lines producing AAV Rep-Cap. Normal Rep78 expression driven by the wild-type p5 promoter has been shown to inhibit AAV production. The purpose of employing different conformations is to reduce Rep78 expression while maintaining Cap expression to maximize AAV production. Glutamine synthetase (GS) cDNA was placed adjacent to the 3' side of Frt5, with optimal RMCE transcription driven by the SV40E promoter located in the landing pad of the Fer1L4 locus. pLMC32 (Fig. 10B) contains a minimal p5 (open box) with the two enhancer elements removed. The complete p5 (closed box) located 3' of the Cap gene enhances Cap expression. pLMC33 (Figure 10C) also has a minimal p5 promoter (white box) (similar to pLMC32), but does not have a p5 promoter 3' of the Cap gene. mutThe p5 promoter (black and grey boxes) contains a mutated (GGGGGGGG) TATA box. pLMC34 (Figure 10D) contains the p5 promoter (black and white boxes) 5' of Rep and a p5 with the TATA box mutated to GGGGGGG. mut The promoters (black and grey boxes) are located at the 3' end of the Cap. pLMC35 (Figure 10E) has TATA mutations in both p5 promoters (black and grey boxes). pLMC32-35 use the GS cDNA selection marker.

[0136] Section 3: Production of rAAV in CHOK1SV GS-KO™ and HEK293 cells by triple transfection with four Rep-Cap constructs

[0146] We examined the ability of GOI (pLMC31) and Rep-Cap (pLMC32-35) expression vectors to sustain rAAV production in CHOK1SV GS-KO™ cells co-infected with wild-type Ad5 virus or HEK293 cells co-transfected with pHelper (6234, Clontech) vectors. Western blot analysis confirmed transduction of wild-type Ad5 into CHOK1SV GS-KO™ cells by E1A protein expression (Figure 11A), and high levels of Rep and Cap protein expression by pLMC31-35 vectors in HEK293 cells, low levels of Rep protein expression, and Cap protein was undetectable in CHOK1SV GS-KO™ cells (Figures 11B and 11C). TaqMan-qPCR analysis showed that these pLMC32-35 vectors increased AAV titers 3-5 fold in HEK293 cells compared to the original Clontech plasmids (5#, pRC2-mi342 (6234, Clontech) and pAAV-GFP), while production levels were low in CHOK1SV GS-KO™ cells (Figure 20). Infectivity assays confirmed qPCR titers and showed high levels of viral transduction in HEK293 samples and low levels of infection in CHOK1SV GS-KO™ samples (Figure 12). In summary, these data confirm the functionality of pLMC32-35 vectors for AAV production in HEK293 and CHO cells and suggest that rAAV production is possible in CHO cells when they are stably expressed.

[0137] Section 4: Generation of CHO cells stably expressing Rep-Cap and GOI by site-specific integration (SSI)

[0147] To determine whether CHOK1SV GS-KO™ SSI hosts with stably integrated GOI and Rep / Cap could support rAAV production, the GOI (pLMC31) and each Rep-Cap vector (pLMC32-35) were transfected into CHOK1SV GS-KO™ SSI hosts along with the FLP recombinase expression vector (pMF4). Two sets of pools were generated by simultaneous or sequential integration of Rep-Cap and GOI (Figure 13). PCR analysis using primers designed to anneal to either the Rep-Cap, the Fer1L landing pad, the GOI, or the NL1 landing pad (Figure 14) demonstrated successful integration of Rep / Cap into the landing pad located in the Fer1L4 gene in the majority of pools (Figure 15A). PCR products of the remaining Fer1L4 landing pads were detected in all but two of the pools (18 and 19 in the "A" pool), indicating complete SSI in these pools (Figure 15B). However, the GOI was only integrated into the landing pad at the NL1 locus in the pool generated by sequential targeting ("B" pool) (Figure 16A), whereas the remaining landing pads were detected in all of the pools (Figure 16B). Western blot analysis identified five pools that stably expressed Rep, whereas Cap protein expression was undetectable (Figure 17). To demonstrate Rep-Cap expression in CHOK1SV GS-KO™ cells, the mRNA expression of these genes was analyzed by TaqMan-qPCR assays using primers to detect different isoforms of Rep and Cap (Figures 18 and 21). CHOK1SV GS-KO™ cells transfected with Rep-Cap2, GOI and pHelper (6234, Clontech) vectors induced ~5-fold higher Rep mRNA levels (Fig. 19A-C) and ~7-fold higher Rep and Cap mRNA levels (Fig. 19D) compared to GOI (pLMC31) and Rep-Cap (pLMC32-35) vectors (Fig. 19A-C).E1A, E1B, E2A, E4 and VA I mRNA levels were detectable only when CHOK1SV GS-KO™ cells were transfected with Rep-Cap2, GOI and pHelper (6234, Clontech), but not with GOI (pLMC31) and Rep-Cap (pLMC32-35) (Figure 19E-J). VA II mRNA levels were not detectable in CHOK1SV GS-KO™ cells (Figure 19K). All observed mRNA levels were lower in CHOK1SV GS-KO™ compared to HEK293 cells, except for E4 (Figure 19A-K). These data indicate that Rep-Cap mRNA induction and expression were lower in CHOK1SV GS-KO™ cells compared to HEK293 cells. In summary, CHOK1SV GS-KO™ cells are capable of expressing Ad5 helper genes and Rep-Cap, but the expression levels of these genes need to be further optimized.

Claims

1. (i) at least four distinct recombination target sites (RTS); (ii) adenovirus (Ad) genes including E1A and E1B; (iii) a promoter operably linked to the Ad genes; (iv) adeno-associated virus (AAV) genes including Rep and Cap, and a second Ad gene including E2A, E4, and VA; the RTS, the Ad gene, the promoter, the AAV gene and the second Ad gene are integrated into a chromosome; the second Ad gene and the AAV gene are located between the two RTSs; Mammalian cells with less than 100 helper viruses per cell.

2. 2. The cell of claim 1 which is a mouse cell, a human cell, a Chinese Hamster Ovary (CHO) cell, a CHO-K1 cell, a CHO-DXB11 cell, a CHO-DG44 cell, a CHOK1SV™ cell including all variants, a CHOK1SV GS-KO™ (Glutamine Synthetase Knockout) cell including all variants, a HEK293 cell including attached and suspension adapted variants, a HeLa cell or a HT1080 cell.

3. The cell of claim 1 or 2, comprising four RTSs.

4. The cell of claim 1 or 2, comprising six RTSs.

5. The cell according to any one of claims 1 to 4, wherein at least one RTS is selected from the group consisting of SEQ ID NOs: 1 to 30.

6. The cell of any one of claims 1 to 5, wherein at least one RTS, the Ad gene and the promoter are integrated into a single chromosomal locus.

7. 7. The cell of claim 6, wherein the chromosomal locus is Fer1L4, ROSA26, HGPRT, DHFR, COSMC, LDHa, MGAT1, GRIK1, NL1, NL2, the first intron of MID1 on the X chromosome, or an expression enhancing and stability region.

8. The cell according to any one of claims 1 to 7, further comprising a site-specific recombinase gene.

9. The cell of claim 8 , wherein the site-specific recombinase gene is integrated into a chromosome.

10. The cell of any one of claims 1 to 9, further comprising an AAV vector cassette, wherein the AAV vector cassette is integrated into a chromosome.

11. The cell of claim 10, wherein the AAV vector cassette comprises a reporter gene, a selection gene, a therapeutic gene, or a combination thereof.

12. a. six distinct recombination target sites (RTS); b. adenovirus (Ad) genes including E1A and E1B; c. a promoter operably linked to the Ad gene; d. a second Ad gene comprising E2A, E4 and VA, said second Ad gene being located between said two RTS; e. an adeno-associated virus (AAV) gene including Rep and Cap, said AAV gene being located between the two RTS; f. an AAV vector cassette containing a reporter gene, a selection gene or a therapeutic gene, located between the two RTSs; Including, the RTS, the Ad gene and the promoter are integrated into a chromosome; Chinese hamster ovary (CHO) cells with less than 100 helper viruses per cell.

13. 1. A method for producing a recombinant adeno-associated virus (rAAV) producer cell, comprising: a. providing a cell comprising at least four distinct recombination target sites (RTS), adenovirus (Ad) genes including E1A and E1B, and a promoter operably linked to said Ad genes, wherein said RTS, said Ad genes and said promoter are integrated into a chromosome; b. transfecting the cells provided in (a) with a vector comprising an exchangeable cassette encoding adeno-associated virus (AAV) genes including Rep and Cap, a second Ad gene including E2A, E4 and VA, an AAV vector cassette, or a combination thereof, wherein the second Ad gene and the AAV gene are located between two of the RTSs; c. integrating the exchangeable cassette into a chromosome; d. Selecting rAAV producer cells having the exchangeable cassette integrated into the chromosome; The method includes:

14. 1. A method for producing a recombinant adeno-associated virus (rAAV), comprising the steps of: (i) infecting a host cell with rAAV; (ii) producing rAAV packaged with an AAV vector cassette; and (iii) purifying the packaged rAAV, wherein the host cell is a. at least four distinct recombination target sites (RTS); b. adenovirus (Ad) genes including E1A and E1B; c. a promoter operably linked to the Ad gene; d. a second Ad gene comprising E2A, E4 and VA; e. adeno-associated virus (AAV) genes including Rep and Cap; f. An AAV vector cassette comprising a reporter gene, a selection gene, a therapeutic gene, or a combination thereof; Including, the RTS, the Ad gene and the promoter are integrated into a chromosome; The method, wherein said second Ad gene and said AAV gene are located between two of said RTSs.

Images